<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001457.pub6" GROUP_ID="NEONATAL" ID="445499090219590250" MERGED_FROM="" MODIFIED="2016-04-18 17:19:50 +0100" MODIFIED_BY="Colleen Ovelman" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2016-04-18 12:18:50 -0400" MODIFIED_BY="Colleen Ovelman">
<TITLE>Glutamine supplementation to prevent morbidity and mortality in preterm infants</TITLE>
<CONTACT>
<PERSON ID="11151" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuire</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Child Health</POSITION>
<EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION>Y010 5DD</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>44 01904 321695</PHONE_1>
<PHONE_2/>
<FAX_1>44 01904 321696</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-04-18 12:18:11 -0400" MODIFIED_BY="Colleen Ovelman">
<PERSON ID="29008725616209149332111102161712" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Thirimon</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moe-Byrne</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>moe.byrne@york.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Centre for Reviews and Dissemination, University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="00537277744985685311111102161515" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jennifer</FIRST_NAME>
<MIDDLE_INITIALS>VE</MIDDLE_INITIALS>
<LAST_NAME>Brown</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>jennifer.brown@york.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Reviews and Dissemination</DEPARTMENT>
<ORGANISATION>University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11151" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuire</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Child Health</POSITION>
<EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION>Y010 5DD</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>44 01904 321695</PHONE_1>
<PHONE_2/>
<FAX_1>44 01904 321696</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-12-15 12:27:56 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="18" MONTH="12" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="12" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-18 12:18:50 -0400" MODIFIED_BY="Colleen Ovelman">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-18 12:18:50 -0400" MODIFIED_BY="Colleen Ovelman">
<DATE DAY="18" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Minor edit</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-01-07 10:40:33 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>Inclusion of a new trial and new follow-up data did not change the conclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-12-15 12:28:13 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="12" YEAR="2015"/>
<DESCRIPTION>
<P>This updates the review "Glutamine supplementation to prevent morbidity and mortality in preterm infants" published in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Moe_x002d_Byrne-2012" TYPE="REFERENCE">Moe-Byrne 2012</LINK>).</P>
<P>Updated search identified one new trial and one publication of follow-up data for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-10-01 10:04:18 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-10-01 10:04:12 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>Further evaluation of routine parenteral glutamine supplementation in preterm infants is unlikely to be considered a research priority, but the inclusion of new trial data in this update provides some support for further trials of enteral glutamine supplementation to be undertaken</P>
<P>New authorship.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-01 10:04:18 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>This updates the review "Glutamine supplementation to prevent morbidity and mortality in preterm infants" published in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Tubman-2008" TYPE="REFERENCE">Tubman 2008</LINK>). </P>
<P>Updated search identified four new trials for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-10-01 10:04:15 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>Feedback on 2008 version of review by Hans Von Rostenberghe (<LINK REF="FBK-01" TYPE="FEEDBACK">Feedback 1</LINK>) incorporated by adding an additional subgroup analysis.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-31 09:45:43 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-10-31 09:45:45 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Feedback incorporated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-12 09:17:25 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>This updates the existing review of "Glutamine supplementation to prevent morbidity and mortality in preterm infants" published in The Cochrane Library, Issue 1, 2005 (Tubman 2005).<BR/>
<BR/>One new trial was identified for this update (Bober-Olesinska 2005). Inclusion of data from this trial did not change the main findings or conclusions of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-10-15 21:34:23 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-07-16 10:43:12 -0400" MODIFIED_BY="Jennifer V E Wagner">
<SOURCE MODIFIED="2011-12-19 07:02:29 -0500" MODIFIED_BY="[Empty name]">
<NAME>Centre for Reviews and Dissemination, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-10-15 21:34:23 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-07-16 10:43:35 -0400" MODIFIED_BY="[Empty name]">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This report is independent research funded by a UK National Institute for Health Research Grant (NIHR) Cochrane Programme Grant (13/89/12). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the UK Department of Health.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-10-15 21:34:23 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-18 12:14:17 -0400" MODIFIED_BY="Colleen Ovelman">
<SUMMARY MODIFIED="2016-04-18 12:14:17 -0400" MODIFIED_BY="Colleen Ovelman">
<TITLE MODIFIED="2008-05-08 11:05:42 -0400" MODIFIED_BY="[Empty name]">Glutamine supplementation to prevent morbidity and mortality in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2016-04-18 12:14:17 -0400" MODIFIED_BY="Colleen Ovelman">
<P>
<B>Review question: </B>In preterm infants, does glutamine supplementation reduce the risk of death or disability?</P>
<P>
<B>Background:</B> Glutamine is an important nutrient for growth and development and may be especially important in protecting preterm infants from infections and gut problems that cause death and disability. We sought evidence that giving preterm infants extra glutamine improves important outcomes.</P>
<P>
<B>Study characteristics: </B>We found 12 randomised controlled trials (enrolling 2877 infants in total). The trials were generally of good methodological quality.</P>
<P>
<B>Key results: </B>These trials did not provide strong or consistent evidence that glutamine supplementation affected the risk of death, serious infection or bowel disease, or longer term development.</P>
<P>
<B>Conclusions:</B> Glutamine supplementation is not likely to be beneficial for preterm infants.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-12-17 12:51:50 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-12-19 06:21:21 -0500" MODIFIED_BY="[Empty name]">
<P>Glutamine is a conditionally essential amino acid. Endogenous biosynthesis may be insufficient for tissue needs in states of metabolic stress. Evidence exists that glutamine supplementation improves clinical outcomes in critically ill adults. It has been suggested that glutamine supplementation may also benefit preterm infants.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of glutamine supplementation on mortality and morbidity in preterm infants.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-12-17 12:51:50 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, 2015, Issue 12), MEDLINE, EMBASE and Maternity and Infant Care (to December 2015), conference proceedings and previous reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised or quasi-randomised controlled trials that compared glutamine supplementation versus no glutamine supplementation in preterm infants at any time from birth to discharge from hospital.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-01-17 12:19:28 -0500" MODIFIED_BY="[Empty name]">
<P>We extracted data using the standard methods of the Cochrane Neonatal Review Group, with separate evaluation of trial quality and data extraction by two review authors. We synthesised data using a fixed-effect model and reported typical relative risk, typical risk difference and weighted mean difference.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-12-15 12:30:21 -0500" MODIFIED_BY="[Empty name]">
<P>We identified 12 randomised controlled trials in which a total of 2877 preterm infants participated. Six trials assessed enteral glutamine supplementation and six trials assessed parenteral glutamine supplementation. The trials were generally of good methodological quality. Meta-analysis did not find an effect of glutamine supplementation on mortality (typical relative risk 0.97, 95% confidence interval 0.80 to 1.17; risk difference 0.00, 95% confidence interval -0.03 to 0.02) or major neonatal morbidities including the incidence of invasive infection or necrotising enterocolitis. Three trials that assessed neurodevelopmental outcomes in children aged 18 to 24 months and beyond did not find any effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-12-19 06:24:27 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>The available trial data do not provide evidence that glutamine supplementation confers important benefits for preterm infants.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-10-15 21:53:59 -0400" MODIFIED_BY="[Empty name]">
<P>Glutamine is the most abundant amino acid in plasma and muscle in humans (<LINK REF="REF-Bergstr_x00f6_m-1974" TYPE="REFERENCE">Bergström 1974</LINK>). Under normal conditions glutamine is the preferred respiratory fuel for rapidly proliferating cells such as enterocytes and lymphocytes (<LINK REF="REF-Windmueller-1982" TYPE="REFERENCE">Windmueller 1982</LINK>; <LINK REF="REF-Newsholme-1985" TYPE="REFERENCE">Newsholme 1985</LINK>). It is a regulator of acid-base balance via ammonium, as well as an important precursor of nucleic acids, nucleotides, amino sugars and protein (<LINK REF="REF-Krebs-1980" TYPE="REFERENCE">Krebs 1980</LINK>).</P>
<INTERVENTION MODIFIED="2015-10-15 21:53:59 -0400" MODIFIED_BY="[Empty name]">
<P>Endogenous biosynthesis of glutamine may be insufficient for tissue needs in states of metabolic stress. In these situations glutamine appears to be "conditionally essential" (<LINK REF="REF-Lacey-1990" TYPE="REFERENCE">Lacey 1990</LINK>). Glutamine is abundant in human milk, but present only in much lower levels in infant formula and not present in standard parenteral nutrition solutions. It has been suggested that glutamine supplementation may benefit preterm infants.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-10-12 19:05:10 -0400" MODIFIED_BY="[Empty name]">
<P>In animal models of experimental enterocolitis, glutamine supplementation has been associated with reduced mucosal damage, improved nitrogen balance, lower rates of sepsis and higher levels of survival (<LINK REF="REF-Klimberg-1990" TYPE="REFERENCE">Klimberg 1990</LINK>; <LINK REF="REF-Rombeau-1990" TYPE="REFERENCE">Rombeau 1990</LINK>). In studies in adult humans, glutamine supplementation has been shown to attenuate gut atrophy in the fasting state, maintain ATP levels in oxidant injured cells, preserve immune cellularity of the gastrointestinal tract during prolonged parenteral feeding and reduce post-operative deterioration in gastrointestinal permeability and mucosal integrity (<LINK REF="REF-O_x0027_Dwyer-1989" TYPE="REFERENCE">O'Dwyer 1989</LINK>; <LINK REF="REF-Hinshaw-1990" TYPE="REFERENCE">Hinshaw 1990</LINK>; <LINK REF="REF-Alverdy-1992" TYPE="REFERENCE">Alverdy 1992</LINK>; <LINK REF="REF-van-der-Hulst-1993" TYPE="REFERENCE">van der Hulst 1993</LINK>). Parenteral glutamine in adults is well tolerated metabolically and appears to have no toxic effects (<LINK REF="REF-Ziegler-1990" TYPE="REFERENCE">Ziegler 1990</LINK>). The findings of systematic reviews of randomised controlled trials in adult surgical or critically ill patients suggest that glutamine supplementation reduces infectious complications and duration of hospital stay and may reduce mortality (<LINK REF="REF-Wischmeyer-2008" TYPE="REFERENCE">Wischmeyer 2008</LINK>; <LINK REF="REF-Avenell-2009" TYPE="REFERENCE">Avenell 2009</LINK>). Systematic reviews of randomised controlled trials found that patients undergoing bone marrow transplantation who receive parenteral nutrition with glutamine versus standard parenteral nutrition have fewer episodes of invasive infection (<LINK REF="REF-Crowther-2009" TYPE="REFERENCE">Crowther 2009</LINK>; <LINK REF="REF-Murray-2009" TYPE="REFERENCE">Murray 2009</LINK>). Larger trials of glutamine supplementation in these populations are ongoing.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-10-12 19:05:47 -0400" MODIFIED_BY="[Empty name]">
<P>Given the findings in studies with adult participants, it is reasonable to hypothesise that glutamine supplementation in preterm infants (particularly very preterm infants) might enhance gastrointestinal mucosal integrity, thus improving enteral feed tolerance, growth and development. Enhanced gastrointestinal barrier function and lymphocyte production might reduce the rate of late-onset invasive infection or necrotising enterocolitis (NEC), and so reduce mortality and adverse neurodevelopmental outcomes.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-10-15 21:55:52 -0400" MODIFIED_BY="[Empty name]">
<P>Our objective was to determine the effects of glutamine supplementation on mortality and morbidity in preterm infants. We prespecified subgroup analyses of enteral and parenteral glutamine supplementation because evidence from systematic reviews of these interventions in adults suggests different effect sizes for various outcomes (<LINK REF="REF-Avenell-2009" TYPE="REFERENCE">Avenell 2009</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-12-17 12:28:05 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-10-15 21:57:27 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-10-15 21:56:47 -0400" MODIFIED_BY="[Empty name]">
<P>We included controlled trials using random or quasi-random participant allocation. Due to the nature of the intervention, we excluded cross-over trials.</P>
<P>Where trials were reported as abstracts only, we aimed to include them provided there was sufficient information to assess eligibility. We contacted the authors requesting further information if we could not decide after reading the abstract.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-10-15 21:57:06 -0400" MODIFIED_BY="[Empty name]">
<P>We included preterm infants (gestational age &lt; 37 weeks) admitted to neonatal intensive or special care units or comparable settings after birth. Where participants in a trial included both term and preterm infants, we sought subgroup data from the report or from the authors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-10-15 21:57:27 -0400" MODIFIED_BY="[Empty name]">
<P>Glutamine supplementation versus no supplementation, administered by the parenteral or enteral route, in addition to a standard nutrition regime.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-10-12 19:19:07 -0400" MODIFIED_BY="[Empty name]">
<P>Studies were included in the review regardless of whether they reported all outcome measures. If a study did not report these outcomes we requested further information from the trial authors.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-10-12 19:11:19 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death prior to hospital discharge.</LI>
<LI>Neurodevelopment:</LI>
<OL>
<LI>Neurodevelopmental outcomes assessed using validated tools at &#8805; 12 months post term.</LI>
<LI>Classifications of disability, including non-ambulant cerebral palsy, developmental delay and auditory and visual impairment.</LI>
<LI>Cognitive and educational outcomes at &#8805; 5 years: intelligence quotient and indices of educational achievement measured using a validated tool (including school examination results).</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-10-12 19:19:07 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Invasive infection during hospital admission as determined by culture of bacteria or fungus from blood, cerebrospinal fluid, urine or from a normally sterile body space (number of participants per group with one or more episodes).</LI>
<LI>NEC during hospital admission including at least two of the following features:</LI>
<OL>
<LI>Pneumatosis coli on abdominal radiograph.</LI>
<LI>Abdominal distension/abdominal radiograph with gaseous distension or frothy appearance of bowel lumen (or both).</LI>
<LI>Blood in stool.</LI>
<LI>Lethargy, hypotonia or apnoea (or combination of these).</LI>
</OL>
<LI>Growth during the trial period: weight gain (g/day or g/kg/day), linear growth (mm/week), head growth (mm/week), skinfold thickness growth (mm/week).</LI>
<LI>Days from birth to establish full enteral tube feeds (at least 150 ml/kg/day), independently of parenteral fluids or nutrition.</LI>
<LI>Days from birth to discharge to home from hospital.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-12-17 12:28:05 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-12-17 12:28:05 -0500" MODIFIED_BY="[Empty name]">
<P>We searched: the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE (OvidSP), Maternity and Infant Care (OvidSP), MEDLINE &amp; MEDLINE in process (OvidSP) and PubMed (until December 2015 updated from previous search in November 2011) using the combination of text words and MeSH terms described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We did not apply language restrictions. Search filters were applied in EMBASE, MEDLINE and PubMed to limit retrieval to clinical trials. </P>
<P>We searched Clinical Trials.gov, metaRegister of Controlled Trials (mRCT), and the WHO International Clinical Trials Registry Platform (ICTRP) for ongoing and completed trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-10-12 19:25:54 -0400" MODIFIED_BY="[Empty name]">
<P>We examined the reference lists of studies identified as potentially relevant. We also searched the abstracts from the annual meetings of the Pediatric Academic Societies (1993 to 2015), the European Society for Pediatric Research (1995 to 2014), the UK Royal College of Paediatrics and Child Health (2000 to 2015) and the Perinatal Society of Australia and New Zealand (2000 to 2014). We considered trials reported only as abstracts to be eligible if sufficient information was available, from the report or from contact with the authors, to fulfil the inclusion criteria.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-12-16 11:54:20 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group.</P>
<STUDY_SELECTION MODIFIED="2015-10-12 19:33:44 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors screened the titles and abstracts of all studies identified by the search. We assessed the full texts of any potentially eligible reports and excluded those studies that did not meet all of the inclusion criteria. We discussed any disagreements until consensus was achieved.<BR/>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-07-16 09:18:05 -0400" MODIFIED_BY="[Empty name]">
<P>We used a data collection form to aid extraction of relevant information from each included study. One author extracted the data and a second author checked the extracted data. Any disagreements were discussed until consensus was achieved. We contacted the investigators for further information if data from the trial reports were insufficient.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-12-16 11:51:48 -0500" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of the Cochrane Neonatal Review Group to assess the methodological quality of any included trials. Two authors conducted the assessment of risk of bias. We resolved disagreements by discussion. We requested additional information from the trial authors to clarify methodology and results if necessary.</P>
<P>We made explicit judgements about whether studies were at high risk of bias across four domains according to the criteria suggested in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<P>1. Random sequence generation - we categorised the method used to generate the allocation sequence as having:</P>
<UL>
<LI>low risk - any truly random process, e.g. random number table, computer random number generator;</LI>
<LI>high risk - any non-random process, e.g. odd or even date of birth, hospital or clinic record number; or</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
<P>2. Allocation concealment - we categorised the method used to conceal the allocation sequence as having:</P>
<UL>
<LI>low risk - e.g. telephone or central randomisation, consecutively numbered sealed opaque envelopes;</LI>
<LI>high risk - open random allocation, e.g. unsealed or non-opaque envelopes, alternation, assignment determined by date of birth; or</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
<P>3. Blinding - we assessed blinding of participants, clinicians and caregivers, and outcome assessors separately for different outcomes and categorised the methods as having:</P>
<UL>
<LI>low risk;</LI>
<LI>high risk; or</LI>
<LI>unclear risk.</LI>
</UL>
<P>4. Incomplete outcome data - we described the completeness of data, including attrition and exclusions from the analysis for each outcome, and any reasons for attrition or exclusion, where reported. We assessed whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we planned to reinstate missing data in the analyses. We categorised completeness as having:</P>
<UL>
<LI>low risk: &#8804; 10% missing data;</LI>
<LI>high risk: &gt; 10% missing data; or</LI>
<LI>unclear risk: no or unclear information provided.</LI>
</UL>
<P>
<B>Quality of evidence</B>
<BR/>We assessed the quality of evidence for the main comparisons at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). This methodological approach considers evidence from randomised controlled trials as high quality that may be downgraded based on consideration of any of five areas: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias. (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: 1) High: We are very confident that the true effect lies close to that of the estimate of the effect; 2) Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; 3) Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; 4) Very Low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>).</P>
<P>Two review authors independently assessed the quality of the evidence found for outcomes identified as critical or important for clinical decision making: mortality and invasive infection.</P>
<P>In cases where we considered the risk of bias arising from inadequate concealment of allocation, randomised assignment, complete follow-up or blinded outcome assessment to reduce our confidence in the effect estimates, we downgraded the quality of evidence accordingly (<LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>). Consistency was evaluated by similarity of point estimates, extent of overlap of confidence intervals and statistical criteria including measurement of heterogeneity (I²). The quality of evidence was downgraded when inconsistency across studies results was present being large and unexplained (some studies suggest important benefit and others no effect or harm without a clinical explanation) (<LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>). Precision was assessed according with the 95% confidence interval around the pooled estimation (<LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>). When trials were conducted in populations other than the target population, we downgraded the quality of evidence because of indirectness (<LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>).</P>
<P>The pooled estimates of the effects and 95% confidence intervals (CI) with explicit judgments for each of the above aspects assessed were entered into the Guideline Development Tool, the software used to create Summary of Findings (SoF) tables (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). All judgements involving the assessment of the study characteristics described above were explained in foot notes or comments in the SoF table.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-10-15 22:10:05 -0400" MODIFIED_BY="[Empty name]">
<P>We calculated relative risk (RR) and risk difference (RD) for dichotomous data and weighted mean difference (WMD) for continuous data, with respective 95% confidence intervals (CI). We determined the number needed to treat for benefit (NNTB) or harm (NNTH) for a statistically significant difference in the RD.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2015-10-12 19:41:27 -0400" MODIFIED_BY="[Empty name]">
<P>We requested outcome data from the trial investigators when these were unavailable in the report. Specifically, we sought unpublished data on the primary outcomes and on the incidence of NEC and invasive infection for all trials. Further information on methodology, especially with regard to the assessment of the risk of bias, was also requested from authors if necessary. The tables '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' report which information was obtained from authors.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-12-16 11:52:54 -0500" MODIFIED_BY="[Empty name]">
<P>We examined the treatment effects of individual trials and heterogeneity between trial results by inspecting the forest plots if more than one trial was included in a meta-analysis. We calculated the I² statistic for each analysis to quantify inconsistency across studies and describe the percentage of variability in effect estimates that may be due to heterogeneity rather than sampling error. If substantial heterogeneity was detected (I² &gt; 50%), we explored the possible causes (for example, differences in study design, participants, interventions, or completeness of outcome assessments).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-12-16 11:52:49 -0500" MODIFIED_BY="[Empty name]">
<P>We inspected a funnel plot for asymmetry if more than ten trials were included in a meta-analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-01-17 12:43:56 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>We used a fixed-effect model for meta-analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-12-16 11:54:20 -0500" MODIFIED_BY="[Empty name]">
<P>We planned the following subgroup analyses:</P>
<OL>
<LI>Route of administration of glutamine supplementation: enteral versus parenteral glutamine administration.</LI>
<LI>Trial setting (country): low- and middle-income versus high-income countries (see: http://data.worldbank.org/about/country-classifications)</LI>
</OL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-12-19 06:29:35 -0500" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>; <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-10-12 19:49:04 -0400" MODIFIED_BY="[Empty name]">
<P>The updated search identified one new eligible trial (<LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>). One publication of relevant follow-up data from <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK> was identified and included in this review (<LINK REF="REF-de-Kieviet-2012" TYPE="REFERENCE">de Kieviet 2012</LINK>). Several other publications of follow-up data were also identified by the searches but were excluded as they did not report any of our prespecified outcomes in addition to data already included in this review.</P>
<P>The trial <LINK REF="STD-NCT00213668" TYPE="STUDY">NCT00213668</LINK> was identified by our search of trial registers. Contact with the trial coordinator revealed that this trial has been completed, however no publication of relevant outcomes could be identified. <LINK REF="STD-NCT01263041" TYPE="STUDY">NCT01263041</LINK> was also identified by our searches as potentially relevant. We were unable to determine who is responsible for this trial and hence do not know the current status of this trial. These trials may be included in an update of this review as results become available.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-12-19 06:29:35 -0500" MODIFIED_BY="[Empty name]">
<P>We included 12 trials that fulfilled the eligibility criteria; nine single-centre studies (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>), one trial in two centres (<LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>) and two larger multi-centre trials (<LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>A total of 2877 preterm infants participated in the included trials; 2082 (72%) of these infants participated in the two largest trials (<LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>). All participating infants were of very or extremely low birth weight and were recruited to a trial within the first few days of postnatal life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Six trials assessed the effect of parenteral glutamine supplementation (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>). The other six trials examined the effect of enteral glutamine supplementation (<LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Reported outcomes included mortality, the incidence of invasive infection, NEC, the duration of parenteral nutrition administration, time taken to establish full enteral nutrition, rate of weight gain and length of hospital admission. <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK> and <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK> reported neurodevelopmental outcomes at 18 and 24 months post term, respectively. <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK> reported neurodevelopmental and cognitive outcomes at seven to eight years of age.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-07-16 11:08:01 -0400" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-12-17 12:55:43 -0500" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2015-10-14 20:49:29 -0400" MODIFIED_BY="[Empty name]">
<P>Eight trials reported adequate allocation concealment methods (randomisation in central pharmacy, computer generated sequence in sealed opaque envelopes; <LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>). Two trials were likely to be "quasi-randomised" and did not report concealment of allocation (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>). Two trial reports did not describe the randomisation and allocation procedure (<LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-12-17 12:55:43 -0500" MODIFIED_BY="[Empty name]">
<P>All apart from two trial reports described the methods used for blinding of caregivers and investigators (<LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-10-14 20:49:29 -0400" MODIFIED_BY="[Empty name]">
<P>Nine trials achieved complete or near-complete levels of follow-up and reported intention-to-treat analyses (<LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>). Two trials did not report the drop out rate (<LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>). <LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK> reported post-recruitment withdrawal of nearly 50% of participants, mainly due to non-compliance with protocol.</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Glutamine supplementation versus no supplementation (parenteral or enteral route)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Death prior to hospital discharge (Analysis 1.1)</HEADING>
<P>None of the individual studies nor a meta-analyses of data from all trials showed a statistically significant difference (typical RR 0.97, 95% CI 0.80 to 1.17; typical RD 0.00, 95% CI -0.03 to 0.02; 12 studies, 2877 infants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was no evidence of statistical heterogeneity or funnel plot asymmetry (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Neurodevelopment (Analysis 1.2)</HEADING>
<P>
<LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK> conducted follow-up assessments of about 89% of the surviving infants at 18 to 22 months post term. This included neurological examination and developmental assessment using Bayley Scales of Infant Development II (BSID-II) Mental, Motor and Behavior Rating Scales. The investigators reported that they did not find any statistically significant differences between the groups for any of the outcomes assessed but numerical data are not published or yet available. Thirty month follow-up on all of these infants was also planned. We could not find these data for inclusion in this review. They will be included in a future update if they become available.</P>
<P>
<LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK> reported neurodevelopmental outcomes for infants aged two years post term. Outcomes assessed included the mental development index (MDI) and psychomotor development index (PDI) subscales of the BSID-II, incidence of cerebral palsy and visual and hearing impairment. No significant differences between the glutamine and the control groups were reported for any of these individual outcomes or for a composite of neurodevelopmental impairment consisting of any of the following: MDI &#8804; 85, PDI &#8804; 85, cerebral palsy, blindness in one or both eyes or hearing loss requiring amplification (RR 1.07, 95% CI 0.59 to 1.92; RD 0.03, 95% CI -0.20 to 0.25; 1 study, 72 infants; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>
<LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK> reported follow-up assessments of 68 children aged 7 to 8 years. Four of these children had serious motor (n = 2), hearing (n = 1), or visual (n = 1) difficulties which prevented them from participating; it is not known if these children received glutamine or placebo. Of the remaining 64 children, 30 had received glutamine after birth and 34 had received placebo. The trial did not show any significant differences in intelligence quotient, processing speed, attention level, working memory and parent- and teacher-rated behavioural outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Invasive infection (Analysis 1.3)</HEADING>
<P>Data were available from eleven trials (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>). Two trials found a statistically significant lower incidence in infants who received glutamine (<LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>), but none of the other trials nor a meta-analysis of all of the data found a statistically significant difference (typical RR 0.94, 95% CI 0.86 to 1.04; typical RD -0.02, 95% CI -0.06 to 0.01; 11 studies, 2815 infants; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was evidence of statistical heterogeneity (I² = 58%) and funnel plot asymmetry (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Necrotising enterocolitis (Analysis 1.4)</HEADING>
<P>None of the eleven individual studies that reported this outcome found a statistically significant difference (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>). Meta-analysis did not reveal a statistically significant difference (typical RR 0.83, 95% CI 0.66 to 1.06; typical RD -0.02, 95% CI -0.04 to 0.00; 11 studies, 2879 infants; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). There was some evidence of statistical heterogeneity (I² = 31%), as well as funnel plot asymmetry (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Growth during the trial period (Analysis 1.5)</HEADING>
<P>Meta-analysis of data from three trials did not reveal a statistically significant difference in the rate of weight gain in grams/day during the study period (WMD 0.59, 95% CI -1.42 to 2.59; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) There was evidence of statistical heterogeneity (I² = 40%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>)<I>. </I>Four trials reported no statistically significant differences in the rate of weight gain or mean weight at the end of the trial period but did not provide data that could be included in meta-analyses (<LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>).</P>
<P>
<LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK> reported that the rate of gain in weight and length and head circumference was higher in the glutamine group than controls up to the end of the 120 day intervention period, but numerical data (including number of participants assessed at each monthly interval) were not available for inclusion in the meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Days from birth to establish full enteral feeds (Analysis 1.6)</HEADING>
<P>Data were available from seven studies (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>). <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK> reported a statistically significant shorter time to full enteral nutrition in the glutamine group while the other studies did not find any significant differences. Meta-analysis of data from all of these trials showed a statistically significant difference between glutamine and control groups in days to full enteral feeds (WMD -1.68, 95% CI -2.88 to -0.48; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Statistical heterogeneity was not evident (I² = 13%), nor was funnel plot asymmetry (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Days from birth to discharge to home from hospital (Analysis 1.7)</HEADING>
<P>Data were available from eight trials (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>). None of the trials nor a meta-analysis of all data found a statistically significant difference between the glutamine and the control group in days from birth to discharge to home in days (WMD -0.85, 95% CI -3.39 to 1.70; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Statistical heterogeneity was not evident (I² = 0%), nor was funnel plot asymmetry (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Enteral glutamine supplementation</HEADING>
<P>Six trials examined the effect of enteral glutamine supplementation (<LINK REF="STD-Neu-1997" TYPE="STUDY">Neu 1997</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>). Meta-analysis of the available data did not show statistically significant effects on mortality or NEC (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Meta-analysis showed a statistically significant lower incidence of invasive infection in the enteral glutamine supplemented group (typical RR 0.76, 95% CI 0.64 to 0.89; typical RD -0.09, 95% CI -0.14 to -0.04; NNTB 11, 05% CI 7 to 25; 6 studies, 1095 infants) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The meta-analysis contained substantial statistical heterogeneity (I² = 56%) which remained in a sensitivity analysis in which the quasi-randomised trial was omitted (<LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>).</P>
<P>Meta-analysis of data from two trials (<LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>) showed a statistically significant difference in time to reach full enteral feeds (WMD -2.63 days, 95% CI -4.99 to -0.27) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Meta-analysis of three trials (<LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>) did not find a statistically significant difference in duration of hospital stay (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Parenteral glutamine supplementation</HEADING>
<P>Six trials examined the effect of parenteral glutamine supplementation (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Thompson-2003" TYPE="STUDY">Thompson 2003</LINK>; <LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>). Meta-analyses did not detect any statistically significant effects on mortality, incidence of invasive infection, incidence of NEC, rate of weight gain, time to full enteral nutrition, or duration of hospital stay (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Substantial heterogeneity was not evident in any of these meta-analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Low- or middle-income countries (Analyses 2.1-2.6)</HEADING>
<P>Three of the trials were undertaken in middle-income countries: Turkey (<LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>), Malaysia (<LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>), and China (<LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>). Meta-analyses did not detect any statistically significant effects on mortality (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), incidence of invasive infection (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), NEC (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), rate of weight gain (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), time to full enteral feeds (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), or duration of hospital stay (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Statistical heterogeneity was not evident in any of these meta-analyses.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-10-15 22:44:24 -0400" MODIFIED_BY="[Empty name]">
<P>The major finding of this review of 12 randomised controlled trials is that glutamine supplementation does not have a statistically significant effect on mortality in preterm infants. The narrow 95% CI around the estimate of effect suggests that a modest but clinically important difference has not been missed. Data from three of the trials also indicate that glutamine supplementation does not have an important effect on neurodevelopmental outcomes. With regard to secondary outcomes, we did not find evidence of an effect on major neonatal morbidities including the rate of invasive infection and the incidence of NEC.</P>
<P>In a pre-specified subgroup analysis, we found that enteral (but not parenteral) glutamine supplementation resulted in a statistically significant reduction in the incidence of invasive infection. However, the meta-analysis contained substantial heterogeneity not explained by variation in study design and methodological quality (randomised versus quasi-randomised). In a meta-analysis of two trials, enteral glutamine supplementation resulted in a 2.6 days reduction in the time taken to achieve full enteral nutrition. Given the potential clinical importance of these findings, further evaluation of enteral glutamine supplementation may be merited as advocated by <LINK REF="REF-van-Zwol-2011" TYPE="REFERENCE">van Zwol 2011</LINK>. Currently, two trials of enteral glutamine supplementation in preterm infants are ongoing and their findings may be incorporated into an update of this review (<LINK REF="STD-NCT00213668" TYPE="STUDY">NCT00213668</LINK>; <LINK REF="STD-NCT01263041" TYPE="STUDY">NCT01263041</LINK>).</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<P>The interpretation of the review findings is limited by the existence of methodological weaknesses associated with the potential for bias in some of the trials (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The main concern is lack of evidence of methods to preserve allocation concealment in four of the trials (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>; <LINK REF="STD-Pawlik-2012" TYPE="STUDY">Pawlik 2012</LINK>). However, in general the trials were of good quality and analyses with quasi-randomised trials omitted did not alter statistical heterogeneity or the overall size of the treatment effects.</P>
<P>The other methodological limitation present in one of the trials was incomplete outcome assessment (<LINK REF="STD-Lacey-1996" TYPE="STUDY">Lacey 1996</LINK>). This trial reported post-recruitment withdrawal of nearly 50% of participants, mainly due to non-compliance with protocol issues. Intention-to-treat re-analysis was not possible. Removal of this trial in sensitivity analyses did not affect the level of heterogeneity or size of treatment effect.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<P>The main concern with the review process is the possibility that the findings are subject to publication and other reporting biases; in other words, that there may be a greater availability of data for inclusion in meta-analyses from trials which reported statistically significant or clinically important effects (<LINK REF="REF-Hopewell-2007a" TYPE="REFERENCE">Hopewell 2007a</LINK>; <LINK REF="REF-Hopewell-2007b" TYPE="REFERENCE">Hopewell 2007b</LINK>; <LINK REF="REF-Hopewell-2009" TYPE="REFERENCE">Hopewell 2009</LINK>). We attempted to minimise this threat by searching the proceedings of the major international perinatal conferences to identify trial reports that were not published in full form in academic journals (<LINK REF="REF-Young-2011" TYPE="REFERENCE">Young 2011</LINK>). However, we cannot be sure that other trials have not been undertaken but not reported, and the concern remains that such trials are less likely than published trials to have detected statistically significant or clinically important effects. Some of the meta-analyses that we performed demonstrated funnel plot asymmetry consistent with possible publication or reporting bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-12-15 12:39:53 -0500" MODIFIED_BY="[Empty name]">
<P>The biologically plausible effects of glutamine supplementation relate to its role in the repair and growth of rapidly dividing cells. This action is consistent with the evidence of benefit of glutamine supplementation in critically ill adult patients (<LINK REF="REF-Wischmeyer-2008" TYPE="REFERENCE">Wischmeyer 2008</LINK>; <LINK REF="REF-Avenell-2009" TYPE="REFERENCE">Avenell 2009</LINK>). Although the population of preterm infants who participated in the trials identified in this review were all of very low birth weight (and of extremely low birth weight in the largest trial), it may be that any benefits of glutamine supplementation are confined to those infants who are critically ill, for example with severe gastrointestinal disease such as NEC. Glutamine supplementation may be beneficial in the recovery phase of these illnesses when infants are severely metabolically compromised and glutamine availability is rate-limiting for tissue repair (<LINK REF="REF-Brown-2014" TYPE="REFERENCE">Brown 2014</LINK>). Additionally, many of the participating infants in the included trials may not have been truly glutamine-deficient as they received glutamine from breast milk, or received glutamate (a precursor for glutamine) from milk, formula, or parenteral nutrition.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-14 20:47:27 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-10-14 20:44:06 -0400" MODIFIED_BY="[Empty name]">
<P>The available data from randomised controlled trials suggests that the routine use of glutamine supplementation does not have an important effect on mortality or neonatal morbidity in preterm infants. Some limited evidence exists that enteral glutamine supplementation reduces the time to reach full enteral nutrition and the rate of late-onset invasive infection in preterm infants; this finding should be interpreted with caution because of the potential for bias in the included trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-10-14 20:47:27 -0400" MODIFIED_BY="[Empty name]">
<P>Follow-up of infants who participated in the trials identified in this review might provide further data on the effect of this intervention on growth through later childhood, specifically later neurodevelopmental outcomes. Further evaluation of routine parenteral glutamine supplementation in preterm infants is unlikely to be considered a research priority, but this review does provide some support for further trials of enteral glutamine supplementation to be undertaken (<LINK REF="REF-van-Zwol-2011" TYPE="REFERENCE">van Zwol 2011</LINK>). It may also be appropriate to focus research effort on assessing the effect of glutamine supplementation as a treatment for preterm infants with severe gastrointestinal disease (<LINK REF="REF-Brown-2014" TYPE="REFERENCE">Brown 2014</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-12-15 12:37:51 -0500" MODIFIED_BY="[Empty name]">
<P>We thank Melissa Harden (Centre for Reviews and Dissemination, University of York) for revising and running the electronic search.</P>
<P>We are very grateful to Drs Brenda Poindexter, Reece Clark, Ruurd van Elburg, Bober-Olesiñska, Ilias Mohamad Ikram, Ayse Korkmaz and Eleftheria Roma-Giannikou for supporting this Cochrane review by discussing aspects of their published findings and for sharing unpublished data (<LINK REF="STD-Poindexter-2004" TYPE="STUDY">Poindexter 2004</LINK>; <LINK REF="STD-van-den-Berg-2005" TYPE="STUDY">van den Berg 2005</LINK>; <LINK REF="STD-Vaughn-2003" TYPE="STUDY">Vaughn 2003</LINK>; <LINK REF="STD-Bober_x002d_Olesi_x00f1_ska-2005" TYPE="STUDY">Bober-Olesiñska 2005</LINK>; <LINK REF="STD-Mohamad-Ikram-2011" TYPE="STUDY">Mohamad Ikram 2011</LINK>; <LINK REF="STD-Korkmaz-2007" TYPE="STUDY">Korkmaz 2007</LINK>; <LINK REF="STD-Sevastiadou-2011" TYPE="STUDY">Sevastiadou 2011</LINK>).</P>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-12-07 10:30:52 -0500" MODIFIED_BY="[Empty name]">
<P>None.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-16 10:42:37 -0400" MODIFIED_BY="[Empty name]">
<P>JVEW, WM and TMB searched and screened the studies for inclusion, assessed the methodological quality of the trials and extracted and entered the relevant information and data from each included study independently. WM and JVEW completed the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-05-21 04:20:32 -0400" MODIFIED_BY="[Empty name]">
<P>None. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-10-15 21:05:13 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-10-15 21:02:24 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bober_x002d_Olesi_x00f1_ska-2005" MODIFIED="2015-10-14 20:49:39 -0400" MODIFIED_BY="[Empty name]" NAME="Bober-Olesiñska 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-10-14 20:49:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bober-Olesiñska K, Kornacka MK</AU>
<TI>Effects of glutamine supplemented parenteral nutrition on the incidence of necrotizing enterocolitis, nosocomial sepsis and length of hospital stay in very low birth weight infants</TI>
<SO>Medycyna Wieku Rozwojowego</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>325-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korkmaz-2007" MODIFIED="2012-02-09 14:15:17 -0500" MODIFIED_BY="Thirimon Moe Byrne" NAME="Korkmaz 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-02-09 14:15:17 -0500" MODIFIED_BY="Thirimon Moe Byrne" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korkmaz A, Yurdakök M, Yi&#287;it S, Tekinalp G</AU>
<TI>Long-term enteral glutamine supplementation in very low birth weight infants: effects on growth parameters</TI>
<SO>Turkish Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>49</VL>
<PG>37-44</PG>
<IDENTIFIERS MODIFIED="2011-11-25 06:26:46 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<IDENTIFIER TYPE="PUBMED" VALUE="17479642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacey-1996" MODIFIED="2015-10-15 20:49:09 -0400" MODIFIED_BY="[Empty name]" NAME="Lacey 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-10-15 20:49:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacey JM, Crouch JB, Benfell K, Ringer SA, Wilmore CK, Maguire D, Wilmore DW</AU>
<TI>The effects of glutamine-supplemented parenteral nutrition in premature infants</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1996</YR>
<VL>20</VL>
<PG>74-80</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:49:09 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:49:09 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8788268"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mohamad-Ikram-2011" MODIFIED="2015-10-15 20:50:53 -0400" MODIFIED_BY="[Empty name]" NAME="Mohamad Ikram 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-10-15 20:50:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamad Ikram I, Quah BS, Noraida R, Djokomuljanto S, Faris Irfan CY, Van Rostenberghe H</AU>
<TI>A randomised controlled trial of glutamine-enriched neonatal parenteral nutrition in Malaysia</TI>
<SO>Singapore Medical Journal</SO>
<YR>2011</YR>
<VL>52</VL>
<PG>356-60</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:50:53 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:50:53 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21633770"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neu-1997" MODIFIED="2015-10-15 20:53:25 -0400" MODIFIED_BY="[Empty name]" NAME="Neu 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-10-15 20:53:25 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hospital costs data on primary publication population&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 20:53:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dallas MJ, Bowling D, Roig JC, Auestad N, Neu J</AU>
<TI>Enteral glutamine supplementation for very-low-birth-weight infants decreases hospital costs</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1998</YR>
<VL>22</VL>
<PG>352-6</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:53:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:53:25 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9829607"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neu J, Roig JC, Meetze WH, Veerman M, Carter C, Millsaps M, et al</AU>
<TI>Enteral glutamine supplementation for very low birth weight infants decreases morbidity</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<PG>691-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 9403648"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-15 20:52:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roig JC, Meetze WH, Auestad N, Jasionowski T, Veerman M, McMurray CA, et al</AU>
<TI>Enteral glutamine supplementation for the very low birthweight infant: plasma amino acid concentrations</TI>
<SO>Journal of Nutrition</SO>
<YR>1996</YR>
<VL>126</VL>
<PG>1115S-20S</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:52:17 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:52:17 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8642443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Pawlik-2012" MODIFIED="2015-10-15 20:54:30 -0400" MODIFIED_BY="[Empty name]" NAME="Pawlik 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-10-15 20:54:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pawlik D, Lauterbach R, Hurkala J, Radziszewska R</AU>
<TI>The effects of enteral administration of glutamine enriched solution in very low birth weight infants on reducing the symptoms of feeding intolerance. A prospective, randomised pilot study</TI>
<TO>Wplyw enteralnej podazy roztworu wzbogaconego glutamina, u noworodkow z bardzo mala urodzeniowa masa ciala, na organiczenie objawow nietolerancji karmienia. Prospektywne, randomizowane badanie pilotazowe</TO>
<SO>Medycyna Wieku Rozwojowego</SO>
<YR>2012</YR>
<VL>XVI</VL>
<NO>3</NO>
<PG>206-11</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:54:30 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:54:30 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23378398"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poindexter-2004" MODIFIED="2015-09-16 09:40:56 -0400" MODIFIED_BY="[Empty name]" NAME="Poindexter 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Poindexter B, Langer J, Dusick A, Ehrenkranz R, for the NICHD Neonatal Research Network</AU>
<TI>Early provision of parenteral amino acids in ELBW infants- relationship with growth and neurodevelopmental outcome at 18 months corrected age</TI>
<SO>Pediatric Research</SO>
<YR>2004</YR>
<VL>55</VL>
<PG>382A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poindexter BB, Ehrenkrantz RA, Stoll BJ, Wright LL, Poole WK, Oh W, et al</AU>
<TI>Parenteral glutamine supplementation does not reduce the risk of morbidity or late-onset sepsis in extremely-low-birthweight infants</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>113</VL>
<PG>1209-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 15121931"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-16 09:40:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, et al</AU>
<TI>Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<NO>3</NO>
<PG>737-43</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:40:15 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:40:15 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12600870"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-16 09:40:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poindexter BB, Langer JC, Dusick AM, Ehrenkranz RA</AU>
<TI>Early provision of parenteral amino acids in extremely low birth weight infants: relation to growth and neurodevelopmental outcome</TI>
<SO>Journal of Pediatrics</SO>
<YR>2006</YR>
<VL>148</VL>
<NO>3</NO>
<PG>300-5</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:40:56 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:40:56 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16615955"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sevastiadou-2011" MODIFIED="2012-02-09 14:14:42 -0500" MODIFIED_BY="Thirimon Moe Byrne" NAME="Sevastiadou 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-09 14:14:42 -0500" MODIFIED_BY="Thirimon Moe Byrne" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sevastiadou S, Malamitsi-Puchner A, Costalos C, Skouroliakou M, Briana DD, Antsaklis A, et al</AU>
<TI>The impact of oral glutamine supplementation on the intestinal permeability and incidence of necrotizing enterocolitis/septicemia in premature neonates</TI>
<SO>Journal of Maternal-Fetal Medicine</SO>
<YR>2011</YR>
<VL>24</VL>
<PG>1294-300</PG>
<IDENTIFIERS MODIFIED="2011-11-25 06:02:24 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<IDENTIFIER TYPE="PUBMED" VALUE="21463215"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2003" MODIFIED="2015-10-15 20:58:22 -0400" MODIFIED_BY="[Empty name]" NAME="Thompson 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-10-15 20:58:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SW, McClure BG, Tubman TRJ</AU>
<TI>A randomised controlled trial of parenteral glutamine in ill very low birth weight neonates</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>550-3</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:58:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:58:22 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14581795"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-den-Berg-2005" MODIFIED="2015-10-15 21:00:41 -0400" MODIFIED_BY="[Empty name]" NAME="van den Berg 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-09-16 09:41:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Kieviet JF, Oosterlaan J, Vermeulen RJ, Pouwels PJW, Lafeber HN, van Elburg RM</AU>
<TI>Effects of glutamine on brain development in very preterm children at school age</TI>
<SO>Pediatrics</SO>
<YR>2012</YR>
<VL>130</VL>
<NO>5</NO>
<PG>e1121-7</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:41:33 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:41:33 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23071202"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-16 09:42:00 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Kieviet JF, Oosterlaan J, van Zwol A, Boehm G, Lafaber HN, van Elburg RM</AU>
<TI>Effects of neonatal enteral glutamine supplementation on cognitive, motor, and behavioural outcomes in very preterm and/or very low birth weight children at school age</TI>
<SO>British Journal of Nutrition</SO>
<YR>2012</YR>
<VL>108</VL>
<NO>12</NO>
<PG>2215-20</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:42:00 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:42:00 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22313936"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-16 09:42:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Kieviet JF, Vujik PJ, van den Berg A, Lafaber HN, Oosterlaan J, van Elburg RM</AU>
<TI>Glutamine effects on brain growth in very preterm children in the first year of life</TI>
<SO>Clinical Nutrition</SO>
<YR>2014</YR>
<VL>33</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:42:34 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:42:34 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23582234"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-15 20:59:23 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Zwol A, van den Berg A, Huisman J, Vermeulen RJ, Fetter WP, Twisk JW, et al</AU>
<TI>Neurodevelopmental outcomes of very low-birth-weight infants after enteral glutamine supplementation in the neonatal period</TI>
<SO>Acta Paediatrica</SO>
<YR>2008</YR>
<VL>97</VL>
<PG>562-7</PG>
<IDENTIFIERS MODIFIED="2015-10-15 20:59:23 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 20:59:23 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18394100"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg A, Fetter WP, Westerbeek EA, van der Vegt IM, van der Molen HR, van Elburg RM</AU>
<TI>The effect of glutamine-enriched enteral nutrition on intestinal permeability in very-low-birth-weight infants: a randomized controlled trial</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2006</YR>
<VL>30</VL>
<PG>408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-17 14:35:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg A, van Elburg RM, Twisk JW, Fetter WP</AU>
<TI>Glutamine-enriched enteral nutrition in very low birth weight infants. Design of a double-blind randomised controlled trial [ISRCTN73254583]</TI>
<SO>BMC Pediatrics</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-15 21:00:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg A, van Elburg RM, Westerbeek EA, Twisk JW, Fetter WP</AU>
<TI>Glutamine-enriched enteral nutrition in very-low-birth-weight infants and effects on feeding tolerance and infectious morbidity: a randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>81</VL>
<PG>1397-404</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:00:41 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:00:41 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15941893"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaughn-2003" MODIFIED="2015-10-15 21:00:57 -0400" MODIFIED_BY="[Empty name]" NAME="Vaughn 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-10-15 21:00:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaughn P, Thomas P, Clark R, Neu J</AU>
<TI>Enteral glutamine supplementation and morbidity in low birth weight infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>142</VL>
<PG>662-8</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:00:57 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:00:57 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12838195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2010" MODIFIED="2015-10-15 21:02:24 -0400" MODIFIED_BY="[Empty name]" NAME="Wang 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-16 10:39:28 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Cai W, Tao YX, Tang QY, Feng Y, Wu J</AU>
<TI>Clinical outcomes of glutamine supplementation in neonates</TI>
<SO>Chinese Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>17</VL>
<PG>259-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-16 11:48:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Cai W, Tao YX, Tang QY, Feng Y, Wu J</AU>
<TI>Glutamine supplementation in preterm infants receiving parenteral nutrition leads to an early improvement in liver function</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2013</YR>
<VL>22</VL>
<NO>4</NO>
<PG>530-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="24231012"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-16 11:48:40 -0400" MODIFIED_BY="Thirimon Moe Byrne" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Tao YX, Cai W, Tang QY, Feng Y, Wu J</AU>
<TI>Protective effect of parenteral glutamine supplementation on hepatic function in very low birth weight infants</TI>
<SO>Clinical Nutrition</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>307-11</PG>
<IDENTIFIERS MODIFIED="2011-11-25 06:57:26 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<IDENTIFIER TYPE="PUBMED" VALUE="20416995"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-10-15 21:04:56 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barbosa-1999" MODIFIED="2015-10-15 21:04:56 -0400" MODIFIED_BY="[Empty name]" NAME="Barbosa 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-10-15 21:04:56 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Abstract only seen. Small randomised controlled trial of glutamine supplementation in nine &amp;quot;seriously ill infants&amp;quot;. Unclear if infants are preterm, likely to be term. No information available from contact with authors (July 2007).&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 21:04:56 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbosa E, Moreira AM, Goes JE, Faintuch J</AU>
<TI>Pilot study with a glutamine-supplemented enteral formula in critically ill infants</TI>
<SO>Revista do Hospital dos Clinicas</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>1</NO>
<PG>21-4</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:04:56 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:04:56 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10488597"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-25 05:56:18 -0500" MODIFIED_BY="Thirimon Moe Byrne"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007" MODIFIED="2011-10-20 12:15:02 -0400" MODIFIED_BY="Thirimon Moe Byrne" NAME="Li 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-20 12:15:02 -0400" MODIFIED_BY="Thirimon Moe Byrne" NOTES="&lt;p&gt;Unclear if allocation was random- no information from contact with authors (July 2007).&lt;/p&gt;" NOTES_MODIFIED="2011-10-20 12:15:02 -0400" NOTES_MODIFIED_BY="Thirimon Moe Byrne" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li ZH, Wang DH, Dong M</AU>
<TI>Effect of parenteral glutamine supplementation in premature infants</TI>
<SO>Chinese Medical Journal</SO>
<YR>2007</YR>
<VL>120</VL>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strujis-2013" MODIFIED="2015-09-16 09:43:52 -0400" MODIFIED_BY="[Empty name]" NAME="Strujis 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-16 09:43:52 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strujis MC, Schaible T, van Elburg RM, Debauche C, te Best H, Tibboel D</AU>
<TI>Efficacy and safety of a parenteral amino acid solution containing alanyl-glutamine versus standard solution in infants: a first-in-man randomised double-blind trial</TI>
<SO>Clinical Nutrition</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>3</NO>
<PG>331-7</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:43:52 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:43:52 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23562219"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-07-16 10:00:01 -0400" MODIFIED_BY="Thirimon Moe Byrne"/>
<ONGOING_STUDIES MODIFIED="2015-10-15 21:05:13 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00213668" MODIFIED="2015-10-15 21:05:13 -0400" MODIFIED_BY="[Empty name]" NAME="NCT00213668" YEAR="">
<REFERENCE MODIFIED="2015-10-15 21:05:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Effect of (enteral) Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2015-10-15 21:05:13 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-07 10:33:03 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<IDENTIFIER MODIFIED="2011-12-07 10:33:03 -0500" MODIFIED_BY="Thirimon Moe Byrne" TYPE="CTG" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01263041" MODIFIED="2011-12-07 10:37:02 -0500" MODIFIED_BY="Thirimon Moe Byrne" NAME="NCT01263041" YEAR="">
<REFERENCE MODIFIED="2011-12-07 10:36:53 -0500" MODIFIED_BY="Thirimon Moe Byrne" PRIMARY="NO" TYPE="OTHER">
<TI>Effect of L-arginine and Glutamine on Preterm (preterm)</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2011</YR>
<IDENTIFIERS MODIFIED="2011-11-16 11:56:23 -0500" MODIFIED_BY="Thirimon Moe Byrne"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-16 12:24:24 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<IDENTIFIER MODIFIED="2011-11-16 12:24:24 -0500" MODIFIED_BY="Thirimon Moe Byrne" TYPE="CTG" VALUE=""/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alverdy-1992" MODIFIED="2015-10-15 21:06:34 -0400" MODIFIED_BY="[Empty name]" NAME="Alverdy 1992" TYPE="JOURNAL_ARTICLE">
<AU>Alverdy JA, Aoys E, Weiss-Carrington P, Burke DA</AU>
<TI>The effect of glutamine-enriched TPN on gut immune cellularity</TI>
<SO>Journal of Surgical Research</SO>
<YR>1992</YR>
<VL>52</VL>
<PG>34-8</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:06:34 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:06:34 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1548865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Avenell-2009" MODIFIED="2012-02-09 14:32:16 -0500" MODIFIED_BY="[Empty name]" NAME="Avenell 2009" TYPE="JOURNAL_ARTICLE">
<AU>Avenell A</AU>
<TI>Hot topics in parenteral nutrition. Current evidence and ongoing trials on the use of glutamine in critically-ill patients and patients undergoing surgery</TI>
<SO>Proceedings of the Nutrition Society</SO>
<YR>2009</YR>
<VL>68</VL>
<PG>261-8</PG>
<IDENTIFIERS MODIFIED="2011-12-05 06:18:19 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19490739"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bergstr_x00f6_m-1974" MODIFIED="2015-10-15 21:08:09 -0400" MODIFIED_BY="[Empty name]" NAME="Bergström 1974" TYPE="JOURNAL_ARTICLE">
<AU>Bergström J, Fürst P, Norée LO, Vinnars E</AU>
<TI>Intracellular free amino acid concentrations in human muscle tissue</TI>
<SO>Journal of Applied Physiology</SO>
<YR>1974</YR>
<VL>36</VL>
<PG>693-7</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:07:41 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:07:41 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="4829908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2014" MODIFIED="2015-10-15 21:12:30 -0400" MODIFIED_BY="[Empty name]" NAME="Brown 2014" TYPE="COCHRANE_REVIEW">
<AU>Brown JV, Moe-Byrne T, McGuire W</AU>
<TI>Glutamine supplementation for young infants with severe gastrointestinal disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-10-15 21:12:30 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:12:30 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005947.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2009" MODIFIED="2012-01-17 14:49:42 -0500" MODIFIED_BY="[Empty name]" NAME="Crowther 2009" TYPE="JOURNAL_ARTICLE">
<AU>Crowther M, Avenell A, Culligan DJ</AU>
<TI>Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2009</YR>
<VL>44</VL>
<PG>413-25</PG>
<IDENTIFIERS MODIFIED="2011-12-05 05:35:20 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19270730"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Kieviet-2012" MODIFIED="2015-09-16 09:44:39 -0400" MODIFIED_BY="[Empty name]" NAME="de Kieviet 2012" TYPE="JOURNAL_ARTICLE">
<AU>de Kieviet JF, Oosterlaan J, van Zwol A, Boehm G, Lafaber HN, van Elburg RM</AU>
<TI>Effects of neonatal enteral glutamine supplementation on cognitive, motor, and behavioural outcomes in very preterm and/or very low birth weight children at school age</TI>
<SO>British Journal of Nutrition</SO>
<YR>2012</YR>
<VL>108</VL>
<NO>12</NO>
<PG>2215-20</PG>
<IDENTIFIERS MODIFIED="2015-09-16 09:44:39 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 09:44:39 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22313936"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro [Version 3.2 for Windows]</TI>
<YR>2008</YR>
<PB>The GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21195583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21247734"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence--imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21839614"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence--inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21803546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence--indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21802903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-05-26 12:33:52 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hinshaw-1990" MODIFIED="2015-10-15 21:12:31 -0400" MODIFIED_BY="[Empty name]" NAME="Hinshaw 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hinshaw DB, Burger JM</AU>
<TI>Protective effect of glutamine on endothelial cell ATP in oxidant injury</TI>
<SO>Journal of Surgical Research</SO>
<YR>1990</YR>
<VL>49</VL>
<PG>222-7</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:12:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:12:31 -0400" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2007a" MODIFIED="2015-10-15 22:54:07 -0400" MODIFIED_BY="[Empty name]" NAME="Hopewell 2007a" TYPE="COCHRANE_REVIEW">
<AU>Hopewell S, Clarke M, Stewart L, Tierney J</AU>
<TI>Time to publication for results of clinical trials</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<PG>MR000011</PG>
<IDENTIFIERS MODIFIED="2015-10-15 22:54:07 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 22:54:07 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000011.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2007b" MODIFIED="2012-01-17 14:53:17 -0500" MODIFIED_BY="[Empty name]" NAME="Hopewell 2007b" TYPE="COCHRANE_REVIEW">
<AU>Hopewell S, McDonald S, Clarke M, Egger M</AU>
<TI>Grey literature in meta-analyses of randomized trials of health care interventions</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-01-17 14:52:57 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-17 14:52:57 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000010.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2009" MODIFIED="2012-01-17 14:54:20 -0500" MODIFIED_BY="[Empty name]" NAME="Hopewell 2009" TYPE="COCHRANE_REVIEW">
<AU>Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K</AU>
<TI>Publication bias in clinical trials due to statistical significance or direction of trial results</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-01-17 14:54:20 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-17 14:54:20 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000006.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Klimberg-1990" MODIFIED="2015-10-15 21:16:58 -0400" MODIFIED_BY="[Empty name]" NAME="Klimberg 1990" TYPE="JOURNAL_ARTICLE">
<AU>Klimberg VS, Salloum RM, Kasper M, Plumley DA, Dolson DJ, Hautamaki RD, et al</AU>
<TI>Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation</TI>
<SO>Archives of Surgery</SO>
<YR>1990</YR>
<VL>125</VL>
<PG>1040-5</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:16:58 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:16:58 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2378557"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krebs-1980" MODIFIED="2011-12-05 05:36:00 -0500" MODIFIED_BY="[Empty name]" NAME="Krebs 1980" TYPE="BOOK_SECTION">
<AU>Krebs H</AU>
<TI>Glutamine metabolism in the animal body</TI>
<SO>Glutamine: metabolism, enzymology and regulation</SO>
<YR>1980</YR>
<PG>319-29</PG>
<ED>Mora J, Palacios R</ED>
<PB>Academic Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lacey-1990" MODIFIED="2015-10-15 21:17:56 -0400" MODIFIED_BY="[Empty name]" NAME="Lacey 1990" TYPE="JOURNAL_ARTICLE">
<AU>Lacey J, Wilmore DW</AU>
<TI>Is glutamine a conditionally essential amino acid?</TI>
<SO>Nutrition Reviews</SO>
<YR>1990</YR>
<VL>48</VL>
<PG>297-309</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:17:56 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:17:56 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2080048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2015-10-15 21:18:53 -0400" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lefebvre C, Eisinga A, McDonald S, Paul N</AU>
<TI>Enhancing access to reports of randomised trials published world-wide - the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library</TI>
<SO>Emerg Themes Epidemiol</SO>
<YR>2008</YR>
<VL>5</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:18:51 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:18:51 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18826567"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-10-15 04:16:22 -0400" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<EN>Version 5.1.0</EN>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-2009" MODIFIED="2012-02-09 14:33:15 -0500" MODIFIED_BY="[Empty name]" NAME="Murray 2009" TYPE="COCHRANE_REVIEW">
<AU>Murray SM, Pindoria S</AU>
<TI>Nutrition support for bone marrow transplant patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-02-09 14:33:15 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-09 14:33:15 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002920.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Newsholme-1985" MODIFIED="2015-10-15 21:19:48 -0400" MODIFIED_BY="[Empty name]" NAME="Newsholme 1985" TYPE="JOURNAL_ARTICLE">
<AU>Newsholme EA, Crabtree B, Ardawi MS</AU>
<TI>Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance</TI>
<SO>Quarterly Journal of Experimental Physiology</SO>
<YR>1985</YR>
<VL>70</VL>
<PG>473-89</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:19:48 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:19:48 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3909197"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Dwyer-1989" MODIFIED="2015-10-15 21:20:32 -0400" MODIFIED_BY="[Empty name]" NAME="O'Dwyer 1989" TYPE="JOURNAL_ARTICLE">
<AU>O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW</AU>
<TI>Maintenance of small bowel mucosa with glutamine enriched parenteral nutrition</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1989</YR>
<VL>13</VL>
<PG>579-85</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:20:32 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:20:32 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2515303"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rombeau-1990" MODIFIED="2015-10-15 21:21:26 -0400" MODIFIED_BY="[Empty name]" NAME="Rombeau 1990" TYPE="JOURNAL_ARTICLE">
<AU>Rombeau JL</AU>
<TI>A review of the effects of glutamine-enriched diets on experimentally induced enterocolitis</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1990</YR>
<VL>14</VL>
<PG>100S-105S</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:21:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:21:26 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2119454"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2015-12-16 11:49:47 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; GWG</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendations</TI>
<SO>Available from www.guidelinedevelopment.org/handbook</SO>
<YR>Updated October 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Hulst-1993" MODIFIED="2015-10-15 21:24:09 -0400" MODIFIED_BY="[Empty name]" NAME="van der Hulst 1993" TYPE="JOURNAL_ARTICLE">
<AU>Van der Hulst RRW, van Kreel BK, von Meyenfeldt MF, Brummer RJM, Arends JW, Deutz NEP, et al</AU>
<TI>Glutamine and the preservation of gut integrity</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>334</VL>
<PG>1363-5</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:24:04 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:24:04 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8098788"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Zwol-2011" MODIFIED="2011-12-19 06:51:25 -0500" MODIFIED_BY="[Empty name]" NAME="van Zwol 2011" TYPE="JOURNAL_ARTICLE">
<AU>van Zwol A, Neu J, van Elburg RM</AU>
<TI>Long-term effects of neonatal glutamine-enriched nutrition in very-low-birth-weight infants</TI>
<SO>Nutrition Reviews</SO>
<YR>2011</YR>
<VL>69</VL>
<PG>2-8</PG>
<IDENTIFIERS MODIFIED="2011-12-15 07:16:58 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21198630"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Windmueller-1982" MODIFIED="2015-10-15 21:25:07 -0400" MODIFIED_BY="[Empty name]" NAME="Windmueller 1982" TYPE="JOURNAL_ARTICLE">
<AU>Windmueller HG</AU>
<TI>Glutamine utilization by the small intestine</TI>
<SO>Advances in Enzymology and Related Areas of Molecular Biology</SO>
<YR>1982</YR>
<VL>53</VL>
<PG>201-37</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:25:07 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:25:07 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7036679"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wischmeyer-2008" MODIFIED="2012-02-09 14:34:54 -0500" MODIFIED_BY="[Empty name]" NAME="Wischmeyer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wischmeyer PE</AU>
<TI>Glutamine: role in critical illness and ongoing clinical trials</TI>
<SO>Current Opinion in Gastroenterology</SO>
<YR>2008</YR>
<VL>24</VL>
<PG>190-7</PG>
<IDENTIFIERS MODIFIED="2011-12-05 06:18:19 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18301270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Young-2011" MODIFIED="2012-02-09 14:35:09 -0500" MODIFIED_BY="[Empty name]" NAME="Young 2011" TYPE="COCHRANE_REVIEW">
<AU>Young T, Hopewell S</AU>
<TI>Methods for obtaining unpublished data</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2012-02-09 14:35:09 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-09 14:35:09 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000027.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-1990" MODIFIED="2015-10-15 21:26:34 -0400" MODIFIED_BY="[Empty name]" NAME="Ziegler 1990" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler TR, Benfell K, Smith RJ, Young LS, Brown E, Ferrari-Baliviera E, et al</AU>
<TI>Safety and metabolic effects of L-glutamine administration in humans</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1990</YR>
<VL>14</VL>
<PG>137S-146S</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:26:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-15 21:26:26 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2119459"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-09-16 09:45:36 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Moe_x002d_Byrne-2012" MODIFIED="2014-10-01 10:02:20 -0400" MODIFIED_BY="[Empty name]" NAME="Moe-Byrne 2012" TYPE="COCHRANE_REVIEW">
<AU>Moe-Byrne T, Brown JVE, McGuire W</AU>
<TI>Glutamine supplementation to prevent morbidity and mortality in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-10-01 10:02:20 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-01 10:02:20 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001457.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tubman-1999" MODIFIED="2015-09-16 09:45:36 -0400" MODIFIED_BY="[Empty name]" NAME="Tubman 1999" TYPE="COCHRANE_REVIEW">
<AU>Tubman TRJ, Thompson SW</AU>
<TI>Glutamine supplementation to prevent morbidity in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-01-17 15:01:49 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-17 15:01:49 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tubman-2001" MODIFIED="2008-06-12 09:21:12 -0400" MODIFIED_BY="[Empty name]" NAME="Tubman 2001" TYPE="COCHRANE_REVIEW">
<AU>Tubman TRJ, Thompson SW</AU>
<TI>Glutamine supplementation to prevent morbidity and mortality in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-06-12 09:21:12 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-12 09:21:12 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001457.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tubman-2005" MODIFIED="2008-05-08 11:16:02 -0400" MODIFIED_BY="[Empty name]" NAME="Tubman 2005" TYPE="COCHRANE_REVIEW">
<AU>Tubman TR, Thompson SW, McGuire W</AU>
<TI>Glutamine supplementation to prevent morbidity and mortality in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-05-08 11:16:02 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-08 11:16:02 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001457.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tubman-2008" MODIFIED="2012-01-17 15:00:09 -0500" MODIFIED_BY="Thirimon Moe Byrne" NAME="Tubman 2008" TYPE="COCHRANE_REVIEW">
<AU>Tubman TR, Thompson SW, McGuire W</AU>
<TI>Glutamine supplementation to prevent morbidity and mortality in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-01-17 15:00:09 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<IDENTIFIER MODIFIED="2012-01-17 15:00:09 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001457.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-06-16 11:48:08 -0400" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-12-19 06:29:04 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-12-19 06:29:04 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-12-16 12:30:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005">
<CHAR_METHODS MODIFIED="2011-10-18 05:26:43 -0400" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>55 very low birth weight infants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:32:21 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: glutamine dipeptide added to standard parenteral nutrition solution to make 20% of total amino acid content (n = 25)</P>
<P>Control: no added glutamine (n = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-17 14:18:32 -0500" MODIFIED_BY="[Empty name]">
<P>Invasive infection and rate of NEC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-16 12:30:27 -0500" MODIFIED_BY="[Empty name]">
<P>Abstract in English. Article in Polish. Further information received courtesy of Dr Bober-Olesiñska.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:32:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korkmaz-2007">
<CHAR_METHODS MODIFIED="2011-12-15 09:28:00 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Quasi-randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-26 18:22:34 -0400" MODIFIED_BY="[Empty name]">
<P>69 very low birth weight infants (appropriate birth weight for gestational age)</P>
<P>Exclusion criteria: congenital malformations, chromosomal abnormalities, inherited metabolic diseases, receipt of enteral feeding for &lt; 1 week or mechanical ventilation for &gt; 4 weeks, those developing post-haemorrhagic hydrocephalus after grade III to IV intra-ventricular haemorrhage</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:32:31 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: enteral glutamine supplementation (300 mg/kg/day) between 8-120 days after birth (n = 36)</P>
<P>Control: sterile water (n = 33)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-14 20:55:30 -0400" MODIFIED_BY="[Empty name]">
<P>Growth parameters (weight, length, head circumference, left upper mid-arm circumference, left mid-thigh circumference during trial period (4 months))</P>
<P>Incidence of invasive infection</P>
<P>Time to full enteral nutrition</P>
<P>Duration of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-17 14:19:11 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Data on mortality and NEC incidence supplied by trial investigators</P>
<P>Setting: Neonatal Intensive Care Unit and neonatal follow-up clinic of Hacettepe University, Ihsan Dogramaci Children's Hospital, Anakara, Turkey (early 2000s)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-19 06:29:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacey-1996">
<CHAR_METHODS MODIFIED="2011-11-29 08:38:29 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-19 06:29:04 -0500" MODIFIED_BY="[Empty name]">
<P>78 infants aged &lt; 4 days, receiving parenteral nutrition for &lt; 3 days<BR/>Must have met &gt; 5 of the following criteria: birth weight &lt; 1500 g, gestational age &lt; 32 weeks, 5-minute Apgar score &lt; 6, need for &gt; 21% oxygen, need for ventilatory assistance, low blood pressure for age, suspected intraventricular haemorrhage, presence of patent ductus arteriosus, presence of umbilical, arterial and venous catheters and birth weight &lt; 1000 g</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:32:38 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: glutamine added to parenteral nutrition solution (n = 38)</P>
<P>Control: parenteral nutrition without added glutamine (n = 39)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-17 14:19:31 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Time to full enteral feeds, duration of administration of parenteral nutrition, duration of mechanical ventilation, average weight gain per day, duration of hospital stay<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-14 21:03:31 -0400" MODIFIED_BY="[Empty name]">
<P>Glutamine was added to parenteral nutrition at concentrations of between 15% and 25% weight per volume of the amino acid mix. The protocol specified that participating infants should continue to receive parenteral nutrition for at least seven days.</P>
<P>Setting: Brigham and Women's Hospital, Boston, USA (early 1990s)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:32:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohamad-Ikram-2011">
<CHAR_METHODS MODIFIED="2011-11-28 05:05:46 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-26 18:21:08 -0400" MODIFIED_BY="[Empty name]">
<P>154 newborn infants aged &lt; 72 hours and receiving parenteral nutrition</P>
<P>Exclusion criteria: chromosomal abnormalities or inborn metabolism errors, those born from consanguineous marriage and those anticipated to require &lt; 48 hours parenteral nutrition</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:32:46 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: 20% glutamine solution added to standard parenteral nutrition (n = 76)</P>
<P>Control: standard parenteral nutrition (n = 78)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-17 14:19:57 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Mortality, invasive infection, NEC, time to full enteral nutrition, time to discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-26 18:47:13 -0400" MODIFIED_BY="[Empty name]">
<P>Trial included term and preterm infants, subgroup data for preterm infants were provided by authors</P>
<P>Setting: Neonatal Intensive Care Unit at Hospital Universiti Sains, Malaysia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:32:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neu-1997">
<CHAR_METHODS MODIFIED="2011-10-20 05:29:32 -0400" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-26 18:46:24 -0400" MODIFIED_BY="[Empty name]">
<P>68 newborn infants (birth weight 500 - 1250 grams, gestational age 24 - 32 weeks) aged &lt; 3 days</P>
<P>Exclusion criteria: congenital anomalies of gastrointestinal tract, NEC, major surgery, breast fed infants, infants considered nonviable</P>
<P>Duration: 3 - 30 days of life<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:32:54 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: enteral glutamine added to commercial preterm formula feed (n = 35)</P>
<P>Control: no added glutamine (n = 33)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-17 14:20:17 -0500" MODIFIED_BY="[Empty name]">
<P>Mortality, invasive infection, NEC, duration of hospital stay<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-14 21:12:40 -0400" MODIFIED_BY="[Empty name]">
<P>The intervention group received 0.08 g/kg/day of glutamine at the start of the study (day 3), increasing to 0.31 g/kg/day by day 13. Glutamine supplementation was stopped on day 30. All infants received the same level of parenteral nutrition (without added glutamine) while enteral feeds were being advanced.</P>
<P>Setting: Neonatal Intensive Care Unit, Shands Hospital at University of Florida, USA<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:33:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pawlik-2012">
<CHAR_METHODS MODIFIED="2014-10-22 09:21:55 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-16 09:42:20 -0400" MODIFIED_BY="[Empty name]">
<P>106 very low birth weight infants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:33:02 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: glutamine/amino acid solution added to usual human milk or formula (n = 50)</P>
<P>Control: human milk or formula without added glutamine (n = 56)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-22 09:39:22 -0400" MODIFIED_BY="[Empty name]">
<P>Feeding intolerance, NEC, intestinal perforation, sepsis, mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-22 09:46:09 -0400" MODIFIED_BY="[Empty name]">
<P>Paper published in Polish with only the abstract and some outcome data available in English. Despite contacting the authors, no further details could be obtained. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:33:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poindexter-2004">
<CHAR_METHODS MODIFIED="2011-10-20 05:42:11 -0400" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-17 14:20:33 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>1433 extremely low birth weight infants enrolled within 72 hours of birth</P>
<P>Exclusion criteria: major congenital anomalies, congenital non-bacterial infection, terminal illness, decision made not to provide full intensive care and support</P>
<P>Duration: birth to 120 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:33:10 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: 20% glutamine added to standard parenteral nutrition solution (n = 721)</P>
<P>Control: no added glutamine (n = 712)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-17 14:20:41 -0500" MODIFIED_BY="[Empty name]">
<P>Primary: Composite outcome of death or late-onset sepsis</P>
<P>Secondary: Number of episodes of late-onset invasive infection, rate of NEC, duration of mechanical ventilation, length of hospital stay, measures of feeding tolerance and intolerance, duration of parenteral nutrition, growth parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-17 14:20:45 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Setting: 15 neonatal care centres in the USA (1999-2001)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:33:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sevastiadou-2011">
<CHAR_METHODS MODIFIED="2011-11-28 05:09:18 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-14 21:15:45 -0400" MODIFIED_BY="[Empty name]">
<P>101 formula fed preterm infants, birth weight &lt; 2 kg, gestational age &lt; 34 weeks</P>
<P>Exclusion criteria: congenital or chromosomal anomalies, severe hypotension, severe perinatal distress, abdominal distention, signs of early NEC</P>
<P>Duration: 3 - 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:33:17 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: 10% glutamine solution, administered enterally 3x daily (n = 51), dosage adjusted to actual weight (0.3 g/kg/day)</P>
<P>Control: isocaloric "caloreen" (glucose polymer) supplementation (n = 50)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-08 05:19:12 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Measures of intestinal permeability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-17 14:21:20 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Unpublished invasive infection and NEC data provided by authors</P>
<P>Setting: Neonatal Intensive Care Unit at Alexandra Regional General Hospital, Greece (2007-8)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:33:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-2003">
<CHAR_METHODS MODIFIED="2011-10-20 06:07:13 -0400" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-17 14:21:28 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>35 very low birth weight infants with a need for mechanical ventilation or more than 40% oxygen enrolled on day one of postnatal life</P>
<P>Exclusion criteria: renal or hepatic dysfunction, suspected congenital anomalies of the gastrointestinal tract, lethal congenital anomalies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:33:25 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: 2.5% glutamine solution given along with standard parenteral nutrition (n = 17), increased to maximum of 3 g/kg/day</P>
<P>Control: sterile water with no added glutamine (n = 18)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-15 20:46:22 -0400" MODIFIED_BY="[Empty name]">
<P>Time to full enteral feeds, number of episodes of sepsis, rate of weight gain, measures of feeding tolerance and intolerance, rate of NEC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-17 14:21:41 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Infants in the intervention group received a solution of 2.5% L-glutamine given as a separate but simultaneous infusion with the remainder of the parenteral nutrition. The glutamine comprised approximately 16% of total amino acids. Control infants received an infusion of water indistinguishable in appearance to the glutamine solution. Parenteral nutrition and glutamine supplementation was discontinued when enteral feeding exceeded 80% of total energy requirements</P>
<P>Setting: Regional Neonatal Unit in Royal Maternity Hospital, Belfast, UK (late 1990s)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:36:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-den-Berg-2005">
<CHAR_METHODS MODIFIED="2011-10-20 06:16:21 -0400" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-26 18:30:41 -0400" MODIFIED_BY="[Empty name]">
<P>107 very low birth weight or very preterm infants</P>
<P>Exclusion criteria: major congenital or chromosomal anomalies, death or transfer to another hospital within 48 hrs of birth, admission from extra regional hospital</P>
<P>Duration: 3 - 30 days of life</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:33:33 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: enteral glutamine supplementation to breast milk or formula (up to 0.3 g/kg/day; n = 54), after two weeks the dosage was adjusted to actual weight of the infants</P>
<P>Control: placebo (alanine) in breast milk or formula (n = 53)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-15 22:33:52 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: time to full enteral feeding</P>
<P>Secondary: other variables of feeding tolerance, NEC, days of no enteral feeding, incidence of serious infection, growth, need for mechanical ventilation, age at discharge, death</P>
<P>
<I>Neurodevelopmental outcomes</I>
</P>
<P>Cognitive development, cerebral palsy, blindness and hearing loss were assessed at 24 months corrected age. Out of the 107 infants initially randomised, 88 were eligible for 2 year follow-up. Data were available for 72 infants (glutamine: n = 40, control: n = 32).</P>
<P>On follow-up at age 7 to 8 years, 68 children were assessed. Four of these children had serious motor (n = 2), hearing (n = 1), or visual (n = 1) difficulties which hindered them from participation. It is not known if these children received glutamine or placebo. Parents and teachers completed questionnaires addressing any behavioural problems at home or in school, respectively. The following cognitive and motor measures were also assessed: the Wechsler Intelligence Scale for Children to assess intellectual development, the Movement Assessment Battery for Children to assess motor development, and an adapted version of the Attention Network Test to assess orienting, executive, and alerting attention.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-15 22:36:31 -0400" MODIFIED_BY="[Empty name]">
<P>After randomisation 5 infants were excluded due to clinical complications, therefore glutamine group n = 52, control n = 50</P>
<P>Setting: Level III Neonatal Intensive Care Unit of VU University Medical Centre, Amsterdam, The Netherlands</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 22:36:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaughn-2003">
<CHAR_METHODS MODIFIED="2011-10-20 06:29:37 -0400" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-14 21:22:33 -0400" MODIFIED_BY="[Empty name]">
<P>649 newborn infants with birth weight 500 - 1250 grams</P>
<P>Exclusion criteria: major chromosomal or congenital anomalies, high probability of death within 3 days, diagnosed with NEC within 7 days after birth</P>
<P>Duration: between 7 days and 36 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 22:36:39 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment: 5 ml/kg of 3% glutamine solution given enterally 12-hourly for the first 28 days (n = 314); dosage not adjusted to weight</P>
<P>Control: sterile water with no added glutamine (n = 335)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-26 18:45:22 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: Number of infants with positive blood cultures from 7 days to 36 weeks postmenstrual age.</P>
<P>Secondary: Number of episodes of sepsis, measures of growth, rates of other neonatal morbidities including NEC, and length of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-17 14:22:50 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Glutamine/control solution given at the same time but separate from milk feeds</P>
<P>Setting: 20 neonatal care centres in the USA (late 1990s)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-14 21:24:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2010">
<CHAR_METHODS MODIFIED="2011-11-28 05:10:16 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-17 14:23:01 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>28 very low birth weight infants receiving parenteral nutrition for at least 7 days</P>
<P>Exclusion criteria: pre-existing renal or hepatic dysfunction, congenital errors of metabolism, major chromosomal disease, cytomegalovirus infection, viral hepatitis, congenital or acquired immune deficiency</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-14 21:24:42 -0400" MODIFIED_BY="[Empty name]">
<P>Intervention: parenteral glutamine 0.3 g/kg/day added to parenteral nutrition</P>
<P>Control: no glutamine (6% amino acid)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-17 14:23:09 -0500" MODIFIED_BY="Thirimon Moe Byrne">
<P>Time to full enteral nutrition, weight gain, head circumference, length of hospitalisation, days on ventilator</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-16 11:12:43 -0400" MODIFIED_BY="Thirimon Moe Byrne">
<P>Data on invasive infection, NEC, time to full enteral nutrition, and duration of hospital stay were requested from the authors (not available May 2014)</P>
<P>Setting: two neonatal care centres in China (mid-late 2000s)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>NEC = necrotising enterocolitis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-10-15 19:34:45 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-11-03 09:14:16 -0400" MODIFIED_BY="Thirimon Moe Byrne" STUDY_ID="STD-Barbosa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-03 09:14:16 -0400" MODIFIED_BY="Thirimon Moe Byrne">
<P>No preterm infants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-15 19:34:36 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-15 19:34:36 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-15 19:34:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strujis-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-15 19:34:45 -0400" MODIFIED_BY="[Empty name]">
<P>Term infants, average gestational age 37 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-07-16 10:00:01 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-10-15 21:05:44 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-10-15 19:36:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00213668">
<CHAR_STUDY_NAME MODIFIED="2011-11-29 09:07:34 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-11-29 09:07:50 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-29 09:08:04 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Premature neonates</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-15 19:35:12 -0400" MODIFIED_BY="[Empty name]">
<P>Dietary supplement: glutamine (dipeptiven)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-15 19:36:17 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure: gastric emptying<BR/>Secondary outcome measures: intestinal transit time, age at total enteral nutrition, age at the end of hospitalisation, variation of cholecystokinin and gastrin postprandial concentration</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-29 09:08:42 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>April 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-29 09:10:24 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Contact: Anne Mercier, MD</P>
<P>02-32-88-80-97 ext 02-33-89-42-62</P>
<P>
<A HREF="mailto:anne.mercier%40ch-avranches-granville.fr?subject=NCT00213668,%202000/111/HP,%20Effect%20of%20Glutamine%20on%20Gastric%20Emptying%20and%20Length%20of%20Parenteral%20Nutrition%20in%20Premature%20Neonates">anne.mercier@ch-avranches-granville.fr</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-29 09:08:57 -0500" MODIFIED_BY="Jennifer V E Wagner"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-10-15 21:05:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01263041">
<CHAR_STUDY_NAME MODIFIED="2015-10-15 21:05:44 -0400" MODIFIED_BY="[Empty name]">
<P>Effect of L-arginine and Glutamine on Preterm (preterm)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-11-29 09:13:01 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-29 09:13:22 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Preterm infants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-29 09:13:34 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Drug: enteral glutamine<BR/>Drug: l-arginine<BR/>Other: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-15 20:48:07 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures: necrotising enterocolitis incidence, sepsis incidence, severity and outcome<BR/>Secondary outcome measures: incidence, severity and outcome of respiratory distress syndrome, pulmonary hypertension, intracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-29 09:13:59 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>December 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-29 09:18:15 -0500" MODIFIED_BY="Jennifer V E Wagner">
<P>Prof. Hesham Awad</P>
<P>Ain Shams University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-12-17 12:56:56 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-12-16 12:27:42 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-16 12:27:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:19:14 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="NO" STUDY_ID="STD-Korkmaz-2007">
<DESCRIPTION>
<P>Quasi-randomised allocation of participants according to the order of admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-15 09:29:35 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="UNKNOWN" STUDY_ID="STD-Lacey-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-28 05:06:09 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Mohamad-Ikram-2011">
<DESCRIPTION>
<P>Randomly permuted blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:20:21 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Neu-1997">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-16 12:27:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pawlik-2012">
<DESCRIPTION>
<P>Methological details were not reported in the abstract. This table will be updated if further details are made available to us by the authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:20:48 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Poindexter-2004">
<DESCRIPTION>
<P>Random sequence generated by data coordination centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-28 05:09:39 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="UNKNOWN" STUDY_ID="STD-Sevastiadou-2011">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:21:45 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Thompson-2003">
<DESCRIPTION>
<P>Four-block randomisation sequence generated off-site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-14 21:23:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaughn-2003">
<DESCRIPTION>
<P>Blocks of 10 for each of 3 birth weight strata</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-28 05:10:47 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>Unique randomisation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:22:26 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-van-den-Berg-2005">
<DESCRIPTION>
<P>Computer generated randomisation table based on blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-12-17 12:56:49 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-16 12:34:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:19:15 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="NO" STUDY_ID="STD-Korkmaz-2007">
<DESCRIPTION>
<P>Quasi-randomised allocation of participants according to the order of admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 12:52:51 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="NO" STUDY_ID="STD-Lacey-1996">
<DESCRIPTION>
<P>First four infants allocated to intervention group and subsequent participants allocated by "balanced assignment" - unclear if this was concealed, may be quasi-randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-26 18:46:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohamad-Ikram-2011">
<DESCRIPTION>
<P>Randomisation sequence was generated by a person who was not directly involved in recruitment or care of the infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:20:22 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Neu-1997">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-17 12:56:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pawlik-2012">
<DESCRIPTION>
<P>Methological details were not reported in the abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-26 18:46:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poindexter-2004">
<DESCRIPTION>
<P>Hospital pharmacists allocated infants to control or glutamine group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-28 05:09:39 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="UNKNOWN" STUDY_ID="STD-Sevastiadou-2011">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 06:13:25 -0400" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Thompson-2003">
<DESCRIPTION>
<P>Hospital pharmacists randomly allocated one solution to be control and one to be glutamine supplemented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 06:35:52 -0400" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Vaughn-2003">
<DESCRIPTION>
<P>Sequentially numbered opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-28 05:10:48 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>Sequentially numbered, sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 14:22:27 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-van-den-Berg-2005">
<DESCRIPTION>
<P>Sealed code batch numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-12-17 12:56:52 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-10-18 05:30:38 -0400" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005">
<DESCRIPTION>
<P>Blinding of intervention and outcome measurement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-28 05:08:44 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="UNKNOWN" STUDY_ID="STD-Korkmaz-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2015-10-14 21:04:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lacey-1996">
<DESCRIPTION>
<P>Investigators, nursing staff and dieticians blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-28 05:06:12 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Mohamad-Ikram-2011">
<DESCRIPTION>
<P>Investigators and treating staff blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-01-17 14:20:23 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Neu-1997">
<DESCRIPTION>
<P>All investigators and caregivers blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2015-12-17 12:56:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pawlik-2012">
<DESCRIPTION>
<P>Methological details were not reported in the abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-01-17 14:20:52 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Poindexter-2004">
<DESCRIPTION>
<P>The caregivers were not aware whether participating infants received glutamine-supplemented or non-supplemented parenteral nutrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-28 05:09:49 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Sevastiadou-2011">
<DESCRIPTION>
<P>Nursing staff blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-10-20 06:13:52 -0400" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Thompson-2003">
<DESCRIPTION>
<P>Main researcher, medical and nursing staff blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-01-17 14:22:52 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Vaughn-2003">
<DESCRIPTION>
<P>Caregivers were not aware which solution infants received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-28 05:10:49 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>Investigators, parents, physicians, nurses blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-01-17 14:22:27 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-van-den-Berg-2005">
<DESCRIPTION>
<P>Investigators, parents, medical and nursing staff were not aware which solution infants received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-12-17 12:56:56 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-16 12:31:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005">
<DESCRIPTION>
<P>Complete follow up assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-28 05:08:40 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="UNKNOWN" STUDY_ID="STD-Korkmaz-2007">
<DESCRIPTION>
<P>Not reported, number presumed to be followed up: 36 and 33</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-15 20:46:14 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lacey-1996">
<DESCRIPTION>
<P>Of the 78 infants originally enrolled, 34 were subsequently excluded for the following reasons: insufficient time on parenteral nutrition (8 treated and 8 control), surgery or transfer (1 treated and 3 control), development of NEC (2 treatment and 2 control) or death (5 treatment and 4 control). One was excluded as a "statistical outlier" (allocation not stated). We have not been able to re-analyse the outcomes for all of the enrolled infants (intention-to-treat).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-16 12:31:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohamad-Ikram-2011">
<DESCRIPTION>
<P>Complete follow up assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-14 21:13:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neu-1997">
<DESCRIPTION>
<P>Of the 68 infants enrolled, 27 were withdrawn from the study for the following reasons: transfer (1 treated and 1 control), illness or intolerance of enteral feeding (9 treated and 16 control). All but the two infants who were transferred from the study centre were included in the analysis whether they were able to adhere completely to the feeding protocol or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-17 12:56:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pawlik-2012">
<DESCRIPTION>
<P>Methological details were not reported in the abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-17 14:20:59 -0500" MODIFIED_BY="Jennifer V E Wagner" RESULT="YES" STUDY_ID="STD-Poindexter-2004">
<DESCRIPTION>
<P>One baby (glutamine) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-17 14:21:24 -0500" MODIFIED_BY="Thirimon Moe Byrne" RESULT="YES" STUDY_ID="STD-Sevastiadou-2011">
<DESCRIPTION>
<P>25 participants exited the study after randomisation (16 in control group: 4 died, in 12 urine collection failed; 9 in glutamine group: 3 died, in 6 urine collection failed)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-14 21:22:14 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2003">
<DESCRIPTION>
<P>5 infants in the glutamine group and 2 in the control group died</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-15 20:46:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaughn-2003">
<DESCRIPTION>
<P>Although 105 (56 treated and 49 control) infants left the study before completing a full course of treatment due to death (39), transfer to another hospital (24), NEC (24), meeting exclusion criteria after enrolment (12), discharge home (2) and parental request (4), outcome analyses in the published report and in this review are intention-to-treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-15 22:36:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>n = 4 from control group and n = 2 from glutamine group were withdrawn</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-26 18:44:40 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-den-Berg-2005">
<DESCRIPTION>
<P>17 (glutamine) and 11 (control) infants were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-10-18 05:48:32 -0400" MODIFIED_BY="Jennifer V E Wagner" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-10-20 05:26:52 -0400" MODIFIED_BY="Jennifer V E Wagner" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-12-19 06:55:27 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-12-19 06:55:27 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-12-19 06:55:19 -0500" MODIFIED_BY="[Empty name]">Glutamine supplementation to prevent morbidity and mortality in preterm infants</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population: </B>Preterm infants<BR/>
<B>Intervention: </B>Glutamine supplementation ¶<BR/>
<B>Comparison: </B>No supplementation</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with no supplementation</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Glutamine supplementation</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Death prior to hospital discharge</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.97<BR/>(0.80 to 1.17)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>2877<BR/>(12 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>123 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>119 per 1000<BR/>(98 to 144)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>80 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>78 per 1000<BR/>(64 to 94)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Neurodevelopmental impairment</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 1.07<BR/>(0.59 to 1.92)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>72<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>375 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>401 per 1000<BR/>(221 to 720)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>375 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>401 per 1000<BR/>(221 to 720)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Invasive infection</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.94<BR/>(0.86 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>2815<BR/>(11 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>368 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>346 per 1000<BR/>(316 to 383)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>364 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>342 per 1000<BR/>(313 to 379)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Necrotising enterocolitis</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.83<BR/>(0.66 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>2849<BR/>(11 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>95 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>79 per 1000<BR/>(63 to 101)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>72 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>59 per 1000<BR/>(47 to 76)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¶ Enteral or parenteral route </P>
<P>
<SUP>1</SUP> Total sample size= 72</P>
<P>
<SUP>2</SUP> Unexplained heterogeneity </P>
<P>
<SUP>3</SUP> Funnel plot asymmetry</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-12-19 06:38:24 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-12-19 06:38:24 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Glutamine supplementation versus no supplementation</NAME>
<DICH_OUTCOME CHI2="6.025238835388089" CI_END="1.1717210968473832" CI_START="0.7955844992108422" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9655066763363701" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="178" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.06882424946811083" LOG_CI_START="-0.09931368705184612" LOG_EFFECT_SIZE="-0.015244718791867635" METHOD="MH" MODIFIED="2015-06-16 12:14:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8131383685921456" P_Q="0.8622277192184443" P_Z="0.7222811423450668" Q="0.03011582502190975" RANDOM="NO" SCALE="30.673379120173312" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1428" TOTAL_2="1449" WEIGHT="100.0" Z="0.35541175780939915">
<NAME>Death prior to hospital discharge</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.454587146234445" CI_END="1.4923722271415918" CI_START="0.5796378097122411" DF="5" EFFECT_SIZE="0.9300727761932027" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="34" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1738771582786112" LOG_CI_START="-0.2368432932943384" LOG_EFFECT_SIZE="-0.03148306750786363" MODIFIED="2015-06-16 12:05:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.630270147140342" P_Z="0.7638146235456108" STUDIES="6" TAU2="0.0" TOTAL_1="538" TOTAL_2="557" WEIGHT="18.850574611281935" Z="0.30047531454515913">
<NAME>Enteral supplementation</NAME>
<DICH_DATA CI_END="2.8725164505239524" CI_START="0.03438640366570043" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45826252451482913" LOG_CI_START="-1.4636132428989304" LOG_EFFECT_SIZE="-0.5026753591920506" MODIFIED="2011-11-25 09:00:57 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="190" O_E="0.0" SE="1.1289193392173218" STUDY_ID="STD-Neu-1997" TOTAL_1="35" TOTAL_2="33" VAR="1.2744588744588745" WEIGHT="1.7356382416183325"/>
<DICH_DATA CI_END="1.7334376565030067" CI_START="0.45599449436278294" EFFECT_SIZE="0.8890658174097664" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.23890822676910534" LOG_CI_START="-0.3410404009370945" LOG_EFFECT_SIZE="-0.05106608708399454" ORDER="193" O_E="0.0" SE="0.34066469470662847" STUDY_ID="STD-Vaughn-2003" TOTAL_1="314" TOTAL_2="335" VAR="0.11605243421956037" WEIGHT="9.78895383712119"/>
<DICH_DATA CI_END="5.987292553082415" CI_START="0.617678995853821" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7772304793057356" LOG_CI_START="-0.20923716657533387" LOG_EFFECT_SIZE="0.28399665636520083" MODIFIED="2011-10-20 10:55:45 -0400" MODIFIED_BY="Thirimon Moe Byrne" ORDER="194" O_E="0.0" SE="0.5794559782841409" STUDY_ID="STD-van-den-Berg-2005" TOTAL_1="52" TOTAL_2="50" VAR="0.33576923076923076" WEIGHT="2.2921444714705594"/>
<DICH_DATA CI_END="7.7227549720641795" CI_START="0.24481224729245332" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8877722557410545" LOG_CI_START="-0.6111668594084917" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2011-11-28 11:59:38 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="61" O_E="0.0" SE="0.8804842561071294" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" VAR="0.7752525252525252" WEIGHT="1.1729033583110222"/>
<DICH_DATA CI_END="3.1197364503945866" CI_START="0.17330227986982172" EFFECT_SIZE="0.7352941176470589" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49411790716786286" LOG_CI_START="-0.7611957239082978" LOG_EFFECT_SIZE="-0.13353890837021748" MODIFIED="2011-11-28 11:59:37 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="63" O_E="0.0" SE="0.7373774407968271" STUDY_ID="STD-Sevastiadou-2011" TOTAL_1="51" TOTAL_2="50" VAR="0.5437254901960783" WEIGHT="2.2703228371267805"/>
<DICH_DATA CI_END="3.474767458221919" CI_START="0.04011139722400277" EFFECT_SIZE="0.37333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5409257456195754" LOG_CI_START="-1.3967322097185368" LOG_EFFECT_SIZE="-0.42790323204948083" MODIFIED="2015-05-21 03:14:55 -0400" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="1.1381898745271768" STUDY_ID="STD-Pawlik-2012" TOTAL_1="50" TOTAL_2="56" VAR="1.2954761904761904" WEIGHT="1.590611865634051"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5650623889468562" CI_END="1.203551010585599" CI_START="0.7878064635059399" DF="4" EFFECT_SIZE="0.973737780564378" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="144" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.08046450187848952" LOG_CI_START="-0.10358046037195419" LOG_EFFECT_SIZE="-0.011557979246732353" MODIFIED="2015-06-16 12:05:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6330245938845032" P_Z="0.8055502266796123" STUDIES="6" TAU2="0.0" TOTAL_1="890" TOTAL_2="892" WEIGHT="81.14942538871807" Z="0.24617053116434523">
<NAME>Parenteral supplementation</NAME>
<DICH_DATA CI_END="4.4179391171695075" CI_START="0.37253091592435095" EFFECT_SIZE="1.2828947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.645219726641909" LOG_CI_START="-0.4288376798064179" LOG_EFFECT_SIZE="0.10819102341774547" MODIFIED="2015-06-16 12:04:37 -0400" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.6309066372176553" STUDY_ID="STD-Lacey-1996" TOTAL_1="38" TOTAL_2="39" VAR="0.3980431848852901" WEIGHT="2.218869123731241"/>
<DICH_DATA CI_END="11.861865612276308" CI_START="0.5907098127948085" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0741529994328203" LOG_CI_START="-0.22862581463868076" LOG_EFFECT_SIZE="0.42276359239706973" MODIFIED="2015-06-16 12:04:41 -0400" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.7652587242447352" STUDY_ID="STD-Thompson-2003" TOTAL_1="17" TOTAL_2="18" VAR="0.5856209150326797" WEIGHT="1.0919171740466898"/>
<DICH_DATA CI_END="1.2071522648109594" CI_START="0.7701287432605148" EFFECT_SIZE="0.9641901558421702" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="127" LOG_CI_END="0.08176205352442568" LOG_CI_START="-0.11343666727701467" LOG_EFFECT_SIZE="-0.015837306876294484" MODIFIED="2015-06-16 12:05:00 -0400" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.1146606948480175" STUDY_ID="STD-Poindexter-2004" TOTAL_1="721" TOTAL_2="712" VAR="0.013147074943030187" WEIGHT="71.82433593977389"/>
<DICH_DATA CI_END="6.235240470368547" CI_START="0.057736345809084974" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7948532072837288" LOG_CI_START="-1.2385507065164414" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2015-06-16 12:04:45 -0400" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.1944315244779278" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005" TOTAL_1="25" TOTAL_2="30" VAR="1.4266666666666665" WEIGHT="1.0218476227709663"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-16 12:04:49 -0400" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8294451941404495" CI_START="0.25589399771075594" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.26231940357999206" LOG_CI_START="-0.5919399008719765" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2015-06-16 12:05:03 -0400" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.5017961440868421" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" VAR="0.25179937022042287" WEIGHT="4.9924555283952925"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9177738330890546" CI_START="0.593280478723136" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.28279738863599774" LOG_CI_START="-0.2267399414355106" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" MODIFIED="2015-06-16 12:06:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8292776333816296" Q="0.0" RANDOM="NO" SCALE="2.0927812835456714" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="32" WEIGHT="100.0" Z="0.21562812201176926">
<NAME>Neurodevelopmental impairment</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9177738330890546" CI_START="0.593280478723136" DF="0" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.28279738863599774" LOG_CI_START="-0.2267399414355106" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2015-06-16 12:06:05 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8292776333816296" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="32" WEIGHT="100.0" Z="0.21562812201176926">
<NAME>Enteral supplementation</NAME>
<DICH_DATA CI_END="1.9177738330890544" CI_START="0.593280478723136" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.2827973886359977" LOG_CI_START="-0.2267399414355106" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2011-12-06 10:09:02 -0500" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.29930474993446615" STUDY_ID="STD-van-den-Berg-2005" TOTAL_1="40" TOTAL_2="32" VAR="0.08958333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-06-16 12:06:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Parenteral supplementation</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.619399918481683" CI_END="1.039457632366498" CI_START="0.8559061813400799" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9432275509036034" ESTIMABLE="YES" EVENTS_1="488" EVENTS_2="521" I2="57.66192183326719" I2_Q="90.6967280385237" ID="CMP-001.03" LOG_CI_END="0.016806792460731926" LOG_CI_START="-0.06757383714447435" LOG_EFFECT_SIZE="-0.025383522341871224" METHOD="MH" MODIFIED="2015-12-15 12:33:24 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.008677321403428362" P_Q="0.001043416394622354" P_Z="0.23831884647443857" Q="10.74890645077212" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1399" TOTAL_2="1416" WEIGHT="100.0" Z="1.1791992978389865">
<NAME>Invasive infection</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.273870086451025" CI_END="0.8920635866966575" CI_START="0.6409338488450999" DF="5" EFFECT_SIZE="0.7561439995371603" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="207" I2="55.64965746758944" ID="CMP-001.03.01" LOG_CI_END="-0.0496041878130697" LOG_CI_START="-0.19318679195398486" LOG_EFFECT_SIZE="-0.12139548988352732" MODIFIED="2015-12-15 12:33:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04621241644643648" P_Z="9.190549299938532E-4" STUDIES="6" TAU2="0.0" TOTAL_1="538" TOTAL_2="557" WEIGHT="39.39647780151171" Z="3.314200762423831">
<NAME>Enteral supplementation</NAME>
<DICH_DATA CI_END="1.0858769724420685" CI_START="0.13098789117334" EFFECT_SIZE="0.37714285714285717" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.03578062339630792" LOG_CI_START="-0.8827688496851593" LOG_EFFECT_SIZE="-0.42349411314442575" MODIFIED="2011-11-24 07:08:43 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="196" O_E="0.0" SE="0.539560507381277" STUDY_ID="STD-Neu-1997" TOTAL_1="35" TOTAL_2="33" VAR="0.2911255411255411" WEIGHT="1.9838477885085957"/>
<DICH_DATA CI_END="1.1433707083132139" CI_START="0.751510971167058" EFFECT_SIZE="0.9269604260206745" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="122" LOG_CI_END="0.05818706195479207" LOG_CI_START="-0.12406467484748747" LOG_EFFECT_SIZE="-0.03293880644634769" MODIFIED="2015-12-15 12:33:24 -0500" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.10705557235830605" STUDY_ID="STD-Vaughn-2003" TOTAL_1="314" TOTAL_2="335" VAR="0.011460895572964504" WEIGHT="22.750659888130023"/>
<DICH_DATA CI_END="0.8999252359671143" CI_START="0.4809571589571021" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" LOG_CI_END="-0.0457935694002813" LOG_CI_START="-0.31789360648926374" LOG_EFFECT_SIZE="-0.1818435879447725" MODIFIED="2011-11-28 11:36:22 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="111" O_E="0.0" SE="0.15983290870297467" STUDY_ID="STD-van-den-Berg-2005" TOTAL_1="52" TOTAL_2="50" VAR="0.02554655870445344" WEIGHT="7.466825200177113"/>
<DICH_DATA CI_END="1.628086247675956" CI_START="0.16852695465318507" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.21167740786128442" LOG_CI_START="-0.7733306270126729" LOG_EFFECT_SIZE="-0.2808266095756942" MODIFIED="2011-12-01 08:19:26 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="65" O_E="0.0" SE="0.5785985955533721" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" VAR="0.3347763347763347" WEIGHT="1.40766938732436"/>
<DICH_DATA CI_END="0.7461787527845447" CI_START="0.23056609935667516" EFFECT_SIZE="0.41478129713423834" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="26" LOG_CI_END="-0.12715712152381828" LOG_CI_START="-0.6372045476252027" LOG_EFFECT_SIZE="-0.38218083457451046" MODIFIED="2011-11-28 11:59:55 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="68" O_E="0.0" SE="0.29960438286743146" STUDY_ID="STD-Sevastiadou-2011" TOTAL_1="51" TOTAL_2="50" VAR="0.08976278623337447" WEIGHT="5.0602429248725045"/>
<DICH_DATA CI_END="2.4227491760512567" CI_START="0.03235993258195265" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.38430845454384666" LOG_CI_START="-1.4899923918594082" LOG_EFFECT_SIZE="-0.5528419686577808" MODIFIED="2015-12-15 12:33:08 -0500" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="1.1009735951160942" STUDY_ID="STD-Pawlik-2012" TOTAL_1="50" TOTAL_2="56" VAR="1.2121428571428572" WEIGHT="0.7272326124991079"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7136559230387705" CI_END="1.201412733317976" CI_START="0.9438009044306317" DF="4" EFFECT_SIZE="1.06484478883074" ESTIMABLE="YES" EVENTS_1="336" EVENTS_2="314" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.07969223055825501" LOG_CI_START="-0.025119610814806743" LOG_EFFECT_SIZE="0.02728630987172415" MODIFIED="2015-06-16 12:07:35 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7882355658487673" P_Z="0.30749192298580663" STUDIES="5" TAU2="0.0" TOTAL_1="861" TOTAL_2="859" WEIGHT="60.6035221984883" Z="1.0204989039210661">
<NAME>Parenteral supplementation</NAME>
<DICH_DATA CI_END="2.693843084137848" CI_START="0.5591262371503313" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.43037229455036236" LOG_CI_START="-0.25249012787680014" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2015-06-16 12:07:21 -0400" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.4011167671572218" STUDY_ID="STD-Lacey-1996" TOTAL_1="22" TOTAL_2="21" VAR="0.16089466089466087" WEIGHT="1.3803889728413299"/>
<DICH_DATA CI_END="1.930032378892969" CI_START="0.2963647188197699" EFFECT_SIZE="0.7563025210084033" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2855645949438316" LOG_CI_START="-0.5281734988502435" LOG_EFFECT_SIZE="-0.1213044519532059" MODIFIED="2015-06-16 12:07:35 -0400" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.4779937843631678" STUDY_ID="STD-Thompson-2003" TOTAL_1="17" TOTAL_2="18" VAR="0.2284780578898226" WEIGHT="1.3104731677233923"/>
<DICH_DATA CI_END="1.236152494001673" CI_START="0.9590143496544664" EFFECT_SIZE="1.0888011664710693" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="273" LOG_CI_END="0.09207204940839747" LOG_CI_START="-0.01817489446736823" LOG_EFFECT_SIZE="0.03694857747051462" MODIFIED="2015-06-16 12:07:24 -0400" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.06475960056379841" STUDY_ID="STD-Poindexter-2004" TOTAL_1="721" TOTAL_2="712" VAR="0.00419380586518272" WEIGHT="52.942072374389085"/>
<DICH_DATA CI_END="1.674277781414625" CI_START="0.34829375527820927" EFFECT_SIZE="0.7636363636363637" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.22382751394835165" LOG_CI_START="-0.4580543121410384" LOG_EFFECT_SIZE="-0.11711339909634337" MODIFIED="2015-06-16 12:07:18 -0400" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.4005407600143841" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005" TOTAL_1="25" TOTAL_2="30" VAR="0.16043290043290043" WEIGHT="1.9271664231226358"/>
<DICH_DATA CI_END="1.7098495044011308" CI_START="0.47165043576912485" EFFECT_SIZE="0.8980263157894737" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.23295788683401322" LOG_CI_START="-0.3263797599700086" LOG_EFFECT_SIZE="-0.04671093656799771" MODIFIED="2015-06-16 12:07:26 -0400" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.3285577024986882" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" VAR="0.1079501638712165" WEIGHT="3.0434212604118507"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.08005710323462" CI_END="1.0564262452937982" CI_START="0.6550850280412175" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8318948350132761" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="136" I2="31.192960940710616" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.023839182050870992" LOG_CI_START="-0.18370232624869864" LOG_EFFECT_SIZE="-0.07993157209891386" METHOD="MH" MODIFIED="2015-06-16 12:08:22 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1590171595563833" P_Q="0.39365528258303506" P_Z="0.13111926556619716" Q="0.7276214530160482" RANDOM="NO" SCALE="169.54" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1415" TOTAL_2="1434" WEIGHT="100.0" Z="1.5097028428203116">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.95338507082465" CI_END="1.079986756318631" CI_START="0.4872509255723393" DF="6" EFFECT_SIZE="0.725413362588615" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="54" I2="39.719000547992536" ID="CMP-001.04.01" LOG_CI_END="0.03341842984527907" LOG_CI_START="-0.31224732723224397" LOG_EFFECT_SIZE="-0.13941444869348243" MODIFIED="2015-06-16 12:08:22 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12662892635602008" P_Z="0.11387999914660539" STUDIES="7" TAU2="0.0" TOTAL_1="576" TOTAL_2="596" WEIGHT="39.348960034330325" Z="1.5809914217360623">
<NAME>Enteral supplementation</NAME>
<DICH_DATA CI_END="6.919500600528848" CI_START="0.15222545101628973" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8400747513554507" LOG_CI_START="-0.8175127305360727" LOG_EFFECT_SIZE="0.011281010409689084" MODIFIED="2011-11-02 10:54:18 -0400" MODIFIED_BY="Thirimon Moe Byrne" ORDER="115" O_E="0.0" SE="0.9736750920534478" STUDY_ID="STD-Lacey-1996" TOTAL_1="38" TOTAL_2="39" VAR="0.9480431848852902" WEIGHT="1.4542696409187272"/>
<DICH_DATA CI_END="2.0300516631548833" CI_START="0.194626593986432" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.30750709049330116" LOG_CI_START="-0.71079781754944" LOG_EFFECT_SIZE="-0.20164536352806942" ORDER="201" O_E="0.0" SE="0.5981573436748961" STUDY_ID="STD-Neu-1997" TOTAL_1="35" TOTAL_2="33" VAR="0.3577922077922078" WEIGHT="4.55022060635755"/>
<DICH_DATA CI_END="2.034765256294025" CI_START="0.7079800979511494" EFFECT_SIZE="1.2002388535031847" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.308514313425305" LOG_CI_START="-0.1499789506032818" LOG_EFFECT_SIZE="0.07926768141101159" MODIFIED="2011-11-24 07:06:18 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="204" O_E="0.0" SE="0.2693212128686521" STUDY_ID="STD-Vaughn-2003" TOTAL_1="314" TOTAL_2="335" VAR="0.07253391570104184" WEIGHT="17.108749352753055"/>
<DICH_DATA CI_END="6.566054899346055" CI_START="0.1408084804636392" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8173045095817735" LOG_CI_START="-0.8513711881793342" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2011-11-24 07:06:17 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="205" O_E="0.0" SE="0.9801883649427954" STUDY_ID="STD-van-den-Berg-2005" TOTAL_1="52" TOTAL_2="50" VAR="0.9607692307692307" WEIGHT="1.5022950573370957"/>
<DICH_DATA CI_END="4.822849873001808" CI_START="0.043557118711160366" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6833037432941281" LOG_CI_START="-1.36094085640089" LOG_EFFECT_SIZE="-0.338818556553381" MODIFIED="2011-11-28 12:00:31 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="70" O_E="0.0" SE="1.200799397034822" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" VAR="1.441919191919192" WEIGHT="1.537465844632613"/>
<DICH_DATA CI_END="0.5127553573232504" CI_START="0.009563863708523882" EFFECT_SIZE="0.0700280112044818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.2900897933803259" LOG_CI_START="-2.019366621499985" LOG_EFFECT_SIZE="-1.1547282074401555" MODIFIED="2011-11-28 12:00:30 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="72" O_E="0.0" SE="1.0157857688958418" STUDY_ID="STD-Sevastiadou-2011" TOTAL_1="51" TOTAL_2="50" VAR="1.0318207282913165" WEIGHT="10.415950536533323"/>
<DICH_DATA CI_END="2.4227491760512567" CI_START="0.03235993258195265" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.38430845454384666" LOG_CI_START="-1.4899923918594082" LOG_EFFECT_SIZE="-0.5528419686577808" MODIFIED="2015-05-21 03:50:11 -0400" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="1.1009735951160942" STUDY_ID="STD-Pawlik-2012" TOTAL_1="50" TOTAL_2="56" VAR="1.2121428571428572" WEIGHT="2.780008995797964"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.286567089020271" CI_END="1.2154471204502846" CI_START="0.6678698182427708" DF="2" EFFECT_SIZE="0.9009774955118639" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="82" I2="39.14622930773027" ID="CMP-001.04.02" LOG_CI_END="0.08473606906482826" LOG_CI_START="-0.17530818232773682" LOG_EFFECT_SIZE="-0.04528605663145427" MODIFIED="2015-06-16 12:08:22 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19334432365841137" P_Z="0.49483077812057297" STUDIES="4" TAU2="0.0" TOTAL_1="839" TOTAL_2="838" WEIGHT="60.651039965669675" Z="0.6826456614532134">
<NAME>Parenteral supplementation</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-16 12:08:12 -0400" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-2003" TOTAL_1="17" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.377867926587785" CI_START="0.7287225737851046" EFFECT_SIZE="1.002039650811781" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="68" LOG_CI_END="0.13920759093658455" LOG_CI_START="-0.13743777703969182" LOG_EFFECT_SIZE="8.84906948446337E-4" MODIFIED="2015-06-16 12:08:17 -0400" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.1625028585659219" STUDY_ID="STD-Poindexter-2004" TOTAL_1="721" TOTAL_2="712" VAR="0.026407179042096014" WEIGHT="50.41039005887702"/>
<DICH_DATA CI_END="1.8696450279285455" CI_START="0.00628394192171157" EFFECT_SIZE="0.10839160839160839" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.271759158918517" LOG_CI_START="-2.201767837508058" LOG_EFFECT_SIZE="-0.9650043392947704" MODIFIED="2015-06-16 12:08:20 -0400" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="1.4529620018570735" STUDY_ID="STD-Bober_x002d_Olesi_x00f1_ska-2005" TOTAL_1="25" TOTAL_2="30" VAR="2.1110985788405143" WEIGHT="3.6964365226583804"/>
<DICH_DATA CI_END="1.6237963528420374" CI_START="0.200209854031078" EFFECT_SIZE="0.5701754385964912" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.2105315616153034" LOG_CI_START="-0.6985145510025375" LOG_EFFECT_SIZE="-0.24399149469361703" MODIFIED="2015-06-16 12:08:22 -0400" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.5339781864025498" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" VAR="0.2851327035537562" WEIGHT="6.544213384134273"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.3269878229243646" CI_END="2.593986345676002" CI_START="-1.4224014565644176" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5857924445557922" ESTIMABLE="YES" I2="39.88556296421804" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2015-06-16 12:09:48 -0400" MODIFIED_BY="Thirimon Moe Byrne" NO="5" P_CHI2="0.1894760139154984" P_Q="1.0" P_Z="0.5675091627865498" Q="0.0" RANDOM="NO" SCALE="8.089886424687238" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="53" UNITS="" WEIGHT="100.0" Z="0.5717237230451594">
<NAME>Rate of weight gain (g/day)</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glutamine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2015-06-16 12:09:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Enteral supplementation</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3269878229243646" CI_END="2.593986345676002" CI_START="-1.4224014565644176" DF="2" EFFECT_SIZE="0.5857924445557922" ESTIMABLE="YES" I2="39.88556296421804" ID="CMP-001.05.02" MODIFIED="2015-06-16 12:09:48 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1894760139154984" P_Z="0.5675091627865498" STUDIES="3" TAU2="0.0" TOTAL_1="47" TOTAL_2="53" WEIGHT="100.0" Z="0.5717237230451594">
<NAME>Parenteral supplementation</NAME>
<CONT_DATA CI_END="2.9547568815133145" CI_START="-2.9547568815133145" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="15.0" MODIFIED="2015-06-16 12:09:46 -0400" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="5.0" SD_2="5.0" SE="1.5075567228888183" STUDY_ID="STD-Lacey-1996" TOTAL_1="22" TOTAL_2="22" WEIGHT="46.19210800905547"/>
<CONT_DATA CI_END="5.981598628820901" CI_START="-0.5815986288208954" EFFECT_SIZE="2.700000000000003" ESTIMABLE="YES" MEAN_1="19.1" MEAN_2="16.4" MODIFIED="2015-06-16 12:09:44 -0400" MODIFIED_BY="[Empty name]" ORDER="206" SD_1="2.9" SD_2="5.8" SE="1.6743157806499147" STUDY_ID="STD-Thompson-2003" TOTAL_1="12" TOTAL_2="16" WEIGHT="37.44901200604432"/>
<CONT_DATA CI_END="2.3651098411257996" CI_START="-7.565109841125799" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="16.0" MODIFIED="2015-06-16 12:09:48 -0400" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="6.4" SD_2="7.0" SE="2.533265856051413" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" WEIGHT="16.358879984900216"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.905246091184475" CI_END="-0.475730937367675" CI_START="-2.8797358649402285" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6777334011539518" ESTIMABLE="YES" I2="13.109541343358492" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2015-12-19 06:34:44 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3296991660753229" P_Q="0.3592031728429189" P_Z="0.006225106676401228" Q="0.8406774248043387" RANDOM="NO" SCALE="20.4486086980294" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="799" TOTAL_2="795" UNITS="" WEIGHT="100.0" Z="2.7356824474082906">
<NAME>Time to full enteral nutrition (days)</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.08025664717347614" CI_END="-0.2676273677906216" CI_START="-4.98851302166773" DF="1" EFFECT_SIZE="-2.6280701947291756" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2015-12-19 06:32:37 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7769499210195732" P_Z="0.029095881888383433" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="83" WEIGHT="25.93126744268932" Z="2.1821850000887304">
<NAME>Enteral supplementation</NAME>
<CONT_DATA CI_END="1.5871638916681774" CI_START="-5.987163891668176" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="14.5" MODIFIED="2011-12-06 11:10:44 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="75" SD_1="7.2" SD_2="8.7" SE="1.932261981108246" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" WEIGHT="10.073549294451666"/>
<CONT_DATA CI_END="0.11845711943579174" CI_START="-5.918457119435793" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="16.0" ORDER="209" SD_1="6.1" SD_2="9.1" SE="1.5400574414861683" STUDY_ID="STD-van-den-Berg-2005" TOTAL_1="52" TOTAL_2="50" WEIGHT="15.857718148237655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.98431201920666" CI_END="0.05162801253770555" CI_START="-2.7416740170546086" DF="4" EFFECT_SIZE="-1.3450230022584515" ESTIMABLE="YES" I2="33.15856547649934" ID="CMP-001.06.02" MODIFIED="2015-12-19 06:32:37 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20032304850419536" P_Z="0.05909138874697692" STUDIES="5" TAU2="0.0" TOTAL_1="711" TOTAL_2="712" WEIGHT="74.06873255731068" Z="1.8875127822745736">
<NAME>Parenteral supplementation</NAME>
<CONT_DATA CI_END="-2.4251741111249867" CI_START="-18.774825888875014" EFFECT_SIZE="-10.600000000000001" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="26.3" MODIFIED="2015-06-16 12:10:23 -0400" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="6.5" SD_2="14.9" SE="4.170906176520078" STUDY_ID="STD-Thompson-2003" TOTAL_1="12" TOTAL_2="16" WEIGHT="2.1619900577453652"/>
<CONT_DATA CI_END="4.591134667122384" CI_START="-6.791134667122387" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="21.3" MODIFIED="2015-06-16 12:10:38 -0400" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="6.4" SD_2="8.9" SE="2.903693492336252" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" WEIGHT="4.460802455734275"/>
<CONT_DATA CI_END="1.3318942030371104" CI_START="-6.131894203037108" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="10.7" MODIFIED="2015-12-19 06:32:37 -0500" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="5.0" SD_2="7.4" SE="1.9040626422086395" STUDY_ID="STD-Lacey-1996" TOTAL_1="22" TOTAL_2="22" WEIGHT="10.374139155544883"/>
<CONT_DATA CI_END="2.0854605023606276" CI_START="-2.685460502360636" EFFECT_SIZE="-0.30000000000000426" ESTIMABLE="YES" MEAN_1="34.8" MEAN_2="35.1" MODIFIED="2015-06-16 12:10:41 -0400" MODIFIED_BY="[Empty name]" ORDER="207" SD_1="20.4" SD_2="21.2" SE="1.2170940492666396" STUDY_ID="STD-Poindexter-2004" TOTAL_1="588" TOTAL_2="581" WEIGHT="25.39020781965835"/>
<CONT_DATA CI_END="0.8955111934127991" CI_START="-3.375511193412796" EFFECT_SIZE="-1.2399999999999984" ESTIMABLE="YES" MEAN_1="8.55" MEAN_2="9.79" MODIFIED="2015-06-16 12:10:42 -0400" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="6.06" SD_2="7.41" SE="1.0895665482924366" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" WEIGHT="31.681593068627805"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9910359487485727" CI_END="1.6990773364385006" CI_START="-3.3931111237480125" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.847016893654756" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2015-12-19 06:38:24 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8858302616490547" P_Q="0.7856897133633692" P_Z="0.514383651510228" Q="0.07393611975465106" RANDOM="YES" SCALE="38.521651975684456" SORT_BY="WEIGHT" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1081" TOTAL_2="1093" UNITS="" WEIGHT="100.0" Z="0.6520271662528017">
<NAME>Duration of hospital stay (days)</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9670382947387275" CI_END="2.917187933362529" CI_START="-5.549670232083519" DF="2" EFFECT_SIZE="-1.316241149360495" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2015-12-19 06:38:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6166096772662334" P_Z="0.542269740582924" STUDIES="3" TAU2="0.0" TOTAL_1="367" TOTAL_2="386" WEIGHT="36.17132080710563" Z="0.6093843069781173">
<NAME>Enteral supplementation</NAME>
<CONT_DATA CI_END="6.130079763602975" CI_START="-22.130079763602975" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="57.0" MEAN_2="65.0" MODIFIED="2011-12-05 12:55:34 -0500" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="37.8" SD_2="30.5" SE="7.20935684280897" STUDY_ID="STD-van-den-Berg-2005" TOTAL_1="45" TOTAL_2="46" WEIGHT="3.246831259452414"/>
<CONT_DATA CI_END="9.219705716189152" CI_START="-12.019705716189156" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" MEAN_1="28.9" MEAN_2="30.3" MODIFIED="2011-12-05 12:55:36 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="79" SD_1="23.9" SD_2="21.1" SE="5.418316764979376" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" WEIGHT="5.7480955817621915"/>
<CONT_DATA CI_END="4.384032642019608" CI_START="-5.384032642019608" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="74.6" MEAN_2="75.1" MODIFIED="2011-12-05 12:58:15 -0500" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="30.8" SD_2="29.8" SE="2.4918991780176745" STUDY_ID="STD-Vaughn-2003" TOTAL_1="286" TOTAL_2="307" WEIGHT="27.176393965891023"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9500615342551941" CI_END="2.6057757265752532" CI_START="-3.7679965013574095" DF="4" EFFECT_SIZE="-0.581110387391078" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2015-12-19 06:38:24 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7449436717864593" P_Z="0.7208012244467894" STUDIES="5" TAU2="0.0" TOTAL_1="714" TOTAL_2="707" WEIGHT="63.82867919289438" Z="0.3573881806874836">
<NAME>Parenteral supplementation</NAME>
<CONT_DATA CI_END="38.42177103708707" CI_START="-24.021771037087095" EFFECT_SIZE="7.199999999999989" ESTIMABLE="YES" MEAN_1="92.6" MEAN_2="85.4" MODIFIED="2015-06-16 12:11:19 -0400" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="47.1" SD_2="33.2" SE="15.929767732142238" STUDY_ID="STD-Thompson-2003" TOTAL_1="12" TOTAL_2="16" WEIGHT="0.6650187286828297"/>
<CONT_DATA CI_END="9.643171956663453" CI_START="-17.64317195666345" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="92.0" MODIFIED="2015-12-19 06:38:24 -0500" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="21.0" SD_2="25.0" SE="6.960929927426755" STUDY_ID="STD-Lacey-1996" TOTAL_1="22" TOTAL_2="22" WEIGHT="3.482717430546088"/>
<CONT_DATA CI_END="9.736697998820546" CI_START="-8.936697998820534" EFFECT_SIZE="0.4000000000000057" ESTIMABLE="YES" MEAN_1="48.7" MEAN_2="48.3" MODIFIED="2015-06-16 12:11:26 -0400" MODIFIED_BY="[Empty name]" ORDER="81" SD_1="11.4" SD_2="13.8" SE="4.7637089622397255" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" WEIGHT="7.436392811613689"/>
<CONT_DATA CI_END="7.072670113423913" CI_START="-3.4726701134238906" EFFECT_SIZE="1.8000000000000114" ESTIMABLE="YES" MEAN_1="99.9" MEAN_2="98.1" MODIFIED="2015-06-16 12:11:23 -0400" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="48.7" SD_2="43.7" SE="2.690187245793316" STUDY_ID="STD-Poindexter-2004" TOTAL_1="597" TOTAL_2="585" WEIGHT="23.317809217164097"/>
<CONT_DATA CI_END="2.2139614729461172" CI_START="-7.253961472946113" EFFECT_SIZE="-2.519999999999998" ESTIMABLE="YES" MEAN_1="13.88" MEAN_2="16.4" MODIFIED="2015-06-16 12:11:21 -0400" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="12.48" SD_2="15.78" SE="2.4153308480599636" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="70" TOTAL_2="69" WEIGHT="28.926741004887674"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-07-16 11:34:45 -0400" MODIFIED_BY="Thirimon Moe Byrne" NO="2">
<NAME>Trials in low- and middle-income countries</NAME>
<DICH_OUTCOME CHI2="0.47440465963552036" CI_END="1.8984653471393396" CI_START="0.35041318519515546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8156269302038295" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="99.99999999999999" ID="CMP-002.01" LOG_CI_END="0.2784026743314828" LOG_CI_START="-0.4554195607523447" LOG_EFFECT_SIZE="-0.08850844321043091" METHOD="MH" MODIFIED="2011-12-07 08:59:48 -0500" MODIFIED_BY="Thirimon Moe Byrne" NO="1" P_CHI2="0.49096780531496065" P_Q="0.0" P_Z="0.6363601837269384" Q="4.146135957717709E-33" RANDOM="NO" SCALE="8.150650476674521" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.47279396215171027">
<NAME>Death prior to hospital discharge</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-25 09:58:26 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="100" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.7227549720641795" CI_START="0.24481224729245332" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8877722557410545" LOG_CI_START="-0.6111668594084917" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2011-11-28 12:03:19 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="98" O_E="0.0" SE="0.8804842561071294" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" VAR="0.7752525252525252" WEIGHT="19.024088943792464"/>
<DICH_DATA CI_END="1.8294451941404495" CI_START="0.25589399771075594" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.26231940357999206" LOG_CI_START="-0.5919399008719765" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2011-11-25 09:58:17 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="99" O_E="0.0" SE="0.5017961440868421" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" VAR="0.25179937022042287" WEIGHT="80.97591105620754"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6575768454411676" CI_END="1.3602157344699626" CI_START="0.4469142032945996" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7796792489732056" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.13360779429633746" LOG_CI_START="-0.3497758428906594" LOG_EFFECT_SIZE="-0.10808402429716095" METHOD="MH" MODIFIED="2011-12-07 08:59:14 -0500" MODIFIED_BY="Thirimon Moe Byrne" NO="2" P_CHI2="0.417417004918477" P_Q="1.0" P_Z="0.3807629713433883" Q="0.0" RANDOM="NO" SCALE="6.1550909963666784" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="111" WEIGHT="100.0" Z="0.8764913771569686">
<NAME>Invasive infection</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.628086247675956" CI_START="0.16852695465318507" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.21167740786128442" LOG_CI_START="-0.7733306270126729" LOG_EFFECT_SIZE="-0.2808266095756942" MODIFIED="2011-11-28 12:03:23 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="101" O_E="0.0" SE="0.5785985955533721" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" VAR="0.3347763347763347" WEIGHT="31.62526892235478"/>
<DICH_DATA CI_END="1.7098495044011308" CI_START="0.47165043576912485" EFFECT_SIZE="0.8980263157894737" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.23295788683401322" LOG_CI_START="-0.3263797599700086" LOG_EFFECT_SIZE="-0.04671093656799771" MODIFIED="2011-11-25 09:59:05 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="102" O_E="0.0" SE="0.3285577024986882" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" VAR="0.1079501638712165" WEIGHT="68.37473107764522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.027621678950321273" CI_END="1.4274688553831059" CI_START="0.21106559270187805" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.548898497014618" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.15456664155339392" LOG_CI_START="-0.6755825583437854" LOG_EFFECT_SIZE="-0.2605079583951958" METHOD="MH" MODIFIED="2011-12-07 08:58:52 -0500" MODIFIED_BY="Thirimon Moe Byrne" NO="3" P_CHI2="0.8680013875382289" P_Q="1.0" P_Z="0.21865702159827183" Q="0.0" RANDOM="NO" SCALE="33.264996162283424" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="111" WEIGHT="100.0" Z="1.230107108948326">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.822849873001808" CI_START="0.043557118711160366" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6833037432941281" LOG_CI_START="-1.36094085640089" LOG_EFFECT_SIZE="-0.338818556553381" MODIFIED="2011-11-28 12:03:28 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="103" O_E="0.0" SE="1.200799397034822" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" VAR="1.441919191919192" WEIGHT="19.024088943792464"/>
<DICH_DATA CI_END="1.6237963528420374" CI_START="0.200209854031078" EFFECT_SIZE="0.5701754385964912" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.2105315616153034" LOG_CI_START="-0.6985145510025375" LOG_EFFECT_SIZE="-0.24399149469361703" MODIFIED="2011-11-25 09:59:36 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="104" O_E="0.0" SE="0.5339781864025498" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" VAR="0.2851327035537562" WEIGHT="80.97591105620754"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.3651098411257996" CI_START="-7.565109841125799" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2011-12-07 08:58:26 -0500" MODIFIED_BY="Thirimon Moe Byrne" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3047298899994805" Q="0.0" RANDOM="NO" SCALE="10.650462358313733" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.026343126912311">
<NAME>Rate of weight gain (g/day)</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.3651098411257996" CI_START="-7.565109841125799" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="16.0" MODIFIED="2011-11-25 10:00:17 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="105" SD_1="6.4" SD_2="7.0" SE="2.533265856051413" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20208396737976805" CI_END="0.3323752808470246" CI_START="-3.2038460173789858" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4357353682659806" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2011-12-07 08:57:53 -0500" MODIFIED_BY="Thirimon Moe Byrne" NO="5" P_CHI2="0.9038951639254534" P_Q="1.0" P_Z="0.1114918155648163" Q="0.0" RANDOM="NO" SCALE="7.170538904619482" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" UNITS="" WEIGHT="100.0" Z="1.5915234799040132">
<NAME>Time to full enteral nutrition (days)</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5871638916681774" CI_START="-5.987163891668176" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="14.5" MODIFIED="2011-11-28 12:03:41 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="106" SD_1="7.2" SD_2="8.7" SE="1.932261981108246" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" WEIGHT="21.796696646458887"/>
<CONT_DATA CI_END="0.8955111934127991" CI_START="-3.375511193412796" EFFECT_SIZE="-1.2399999999999984" ESTIMABLE="YES" MEAN_1="8.55" MEAN_2="9.79" MODIFIED="2011-11-25 10:01:05 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="107" SD_1="6.06" SD_2="7.41" SE="1.0895665482924366" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="76" TOTAL_2="78" WEIGHT="68.55121796781"/>
<CONT_DATA CI_END="4.591134667122384" CI_START="-6.791134667122387" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="21.3" MODIFIED="2011-11-25 10:01:19 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="108" SD_1="6.4" SD_2="8.9" SE="2.903693492336252" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" WEIGHT="9.652085385731109"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3069320199231912" CI_END="2.0720352195067107" CI_START="-5.77499830732164" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.851481543907465" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2011-12-07 08:57:40 -0500" MODIFIED_BY="Thirimon Moe Byrne" NO="6" P_CHI2="0.8577299338869913" P_Q="1.0" P_Z="0.3550210546793384" Q="0.0" RANDOM="NO" SCALE="12.994449859253763" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="117" UNITS="" WEIGHT="100.0" Z="0.9248940078292149">
<NAME>Duration of hospital stay (days)</NAME>
<GROUP_LABEL_1>Glutamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.219705716189152" CI_START="-12.019705716189156" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" MEAN_1="28.9" MEAN_2="30.3" MODIFIED="2011-11-28 12:03:51 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="109" SD_1="23.9" SD_2="21.1" SE="5.418316764979376" STUDY_ID="STD-Korkmaz-2007" TOTAL_1="36" TOTAL_2="33" WEIGHT="13.649792855487647"/>
<CONT_DATA CI_END="2.2139614729461172" CI_START="-7.253961472946113" EFFECT_SIZE="-2.519999999999998" ESTIMABLE="YES" MEAN_1="13.88" MEAN_2="16.4" MODIFIED="2011-11-25 10:06:45 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="110" SD_1="12.48" SD_2="15.78" SE="2.4153308480599636" STUDY_ID="STD-Mohamad-Ikram-2011" TOTAL_1="70" TOTAL_2="69" WEIGHT="68.69127645577704"/>
<CONT_DATA CI_END="9.736697998820546" CI_START="-8.936697998820534" EFFECT_SIZE="0.4000000000000057" ESTIMABLE="YES" MEAN_1="48.7" MEAN_2="48.3" MODIFIED="2011-11-25 10:02:00 -0500" MODIFIED_BY="Thirimon Moe Byrne" ORDER="111" SD_1="11.4" SD_2="13.8" SE="4.7637089622397255" STUDY_ID="STD-Wang-2010" TOTAL_1="13" TOTAL_2="15" WEIGHT="17.658930688735314"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome: 1.1 Death prior to hospital discharge.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.03" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome: 1.3 Invasive infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.04" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome: 1.4 Necrotising enterocolitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.06" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome: 1.6 Time to full enteral nutrition (days).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.07" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Glutamine supplementation versus no supplementation, outcome: 1.7 Duration of hospital stay (days).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-01-07 10:31:43 -0500" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAQ0AAAKCCAIAAABEfhvPAAAdBUlEQVR42u3dv24kxdfG8ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-07-16 11:11:43 -0400" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-07-16 11:11:43 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-05-08 10:57:46 -0400" MODIFIED_BY="[Empty name]">Hans Van Rostenberghe Feedback and Review Author Response</TITLE>
<DATE_SUBMITTED>
<DATE DAY="11" MONTH="9" YEAR="2007"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2008-05-08 10:59:40 -0400" MODIFIED_BY="[Empty name]">
<P>Glutamine has been shown to be a very useful additive to parenteral nutrition in adults. For neonates, it may be useful to consider the potential differences between developed and developing nations. Differences in nutritional status of the mothers may result in less available glutamine for the neonate. Furthermore infection rates tend to be a lot higher in settings of developing nations. Large trials in a developing nation may be still very useful to perform. </P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-07-16 11:11:16 -0400" MODIFIED_BY="[Empty name]">
<P>Thank you for highlighting that the findings of studies undertaken in high-income countries may not be wholly applicable to infants in low-and middle-income countries. We have pre-specified subgroup analyses of studies undertaken in low- and middle-income countries in the 2011 update of this review.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-07-16 11:11:43 -0400" MODIFIED_BY="[Empty name]">
<P>Thirimon Moe Byrne, Jennifer VE Wagner, William McGuire.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-12-17 12:37:40 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-12-17 12:37:40 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-11-29 09:21:22 -0500" MODIFIED_BY="Jennifer V E Wagner">Electronic search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-17 12:37:40 -0500" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Database searches</B>
</I>
</P>
<P>
<B>Cochrane Central Register of Controlled Trials (CENTRAL)</B>
</P>
<P>Wiley <A HREF="http://onlinelibrary.wiley.com/">http://onlinelibrary.wiley.com/</A>
</P>
<P>#1 MeSH descriptor: [Infant, Newborn] explode all trees </P>
<P>#2 MeSH descriptor: [Premature Birth] this term only </P>
<P>#3 (neonat* or neo next nat*):ti,ab,kw </P>
<P>#4 (newborn* or new next born* or newly next born*):ti,ab,kw </P>
<P>#5 (preterm or preterms or pre next term or pre next terms):ti,ab,kw</P>
<P>#6 (preemie* or premie or premies):ti,ab,kw </P>
<P>#7 (prematur* near/3 (birth* or born or deliver*)):ti,ab,kw </P>
<P>#8 (low near/3 (birthweight* or birth next weight*)):ti,ab,kw </P>
<P>#9 (lbw or vlbw or elbw):ti,ab,kw </P>
<P>#10 infan*:ti,ab,kw </P>
<P>#11 (baby or babies):ti,ab,kw </P>
<P>#12 MeSH descriptor: [Enterocolitis, Necrotizing] this term only </P>
<P>#13 enterocolitis:ti,ab,kw </P>
<P>#14 NEC:ti,ab,kw </P>
<P>#15 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 </P>
<P>#16 MeSH descriptor: [Glutamine] this term only</P>
<P>#17 glutam*:ti,ab,kw </P>
<P>#18 levoglutam*:ti,ab,kw </P>
<P>#19 #16 or #17 or #18 </P>
<P>#20 #15 and #19 </P>
<P>#21 #15 and #19 in Trials </P>
<P>#22 #15 and #19 Publication Year from 2007 to 2015, in Trials </P>
<P>
<B>Key</B>
</P>
<P>MeSH descriptor = indexing term (MeSH heading)</P>
<P>* = truncation</P>
<P>:ti,ab,kw = terms in either title or abstract or keyword fields</P>
<P>near/3 = terms within three words of each other (any order)</P>
<P>next = terms are next to each other</P>
<P>
<B>EMBASE</B>
</P>
<P>OvidSP <A HREF="http://ovidsp.ovid.com/">http://ovidsp.ovid.com/</A>
</P>
<P>A search strategy developed by <LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK> to identify randomised trials in EMBASE was used to limit retrieval to clinical trials (lines 22-36).</P>
<P>1 exp infant/ </P>
<P>2 prematurity/ </P>
<P>3 premature labor/ </P>
<P>4 exp low birth weight/ </P>
<P>5 (neonat$ or neo nat$).ti,ab. </P>
<P>6 (newborn$ or new born$ or newly born$).ti,ab. </P>
<P>7 (preterm or preterms or pre term or pre terms).ti,ab. </P>
<P>8 (preemie$ or premie or premies).ti,ab. </P>
<P>9 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. </P>
<P>10 (low adj3 (birthweight$ or birth weight$)).ti,ab.</P>
<P>11 (lbw or vlbw or elbw).ti,ab. </P>
<P>12 infan$.ti,ab. </P>
<P>13 (baby or babies).ti,ab. </P>
<P>14 necrotizing enterocolitis/ </P>
<P>15 enterocolitis.ti,ab.</P>
<P>16 NEC.ti,ab.</P>
<P>17 or/1-16 </P>
<P>18 glutamine/ </P>
<P>19 glutam$.ti,ab. </P>
<P>20 levoglutam$.ti,ab. </P>
<P>21 18 or 19 or 20 </P>
<P>22 random$.ti,ab. </P>
<P>23 factorial$.ti,ab. </P>
<P>24 crossover$.ti,ab. </P>
<P>25 cross-over$.ti,ab. </P>
<P>26 placebo$.ti,ab.</P>
<P>27 (doubl$ adj blind$).ti,ab. </P>
<P>28 (singl$ adj blind$).ti,ab. </P>
<P>29 assign$.ti,ab. </P>
<P>30 allocat$.ti,ab.</P>
<P>31 volunteer$.ti,ab.</P>
<P>32 Crossover Procedure/ </P>
<P>33 double blind procedure/ </P>
<P>34 Randomized Controlled Trial/</P>
<P>35 single blind procedure/ </P>
<P>36 or/22-35 </P>
<P>37 17 and 21 and 36</P>
<P>38 animal/ </P>
<P>39 exp animal experiment/ </P>
<P>40 Nonhuman/ </P>
<P>41 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh. </P>
<P>42 38 or 39 or 40 or 41</P>
<P>43 exp human/</P>
<P>44 human experiment/ </P>
<P>45 43 or 44 </P>
<P>46 42 not (42 and 45)</P>
<P>47 37 not 46 </P>
<P>48 limit 47 to em</P>
<P>
<B>Key:</B>
</P>
<P>/ = indexing term (EMTREE heading)</P>
<P>$ = truncation</P>
<P>.ti,ab. = terms in either title or abstract fields</P>
<P>adj3 = terms within three words of each other (any order)</P>
<P>.sh.= subject heading field</P>
<P>.em. = entry date &#8211; date added to database</P>
<P>
<B>Maternity and Infant Care </B>
</P>
<P>OvidSP <A HREF="http://ovidsp.ovid.com/">http://ovidsp.ovid.com/</A>
</P>
<P>1 Infant.de.</P>
<P>2 Infant - newborn.de. </P>
<P>3 Infant - premature.de. </P>
<P>4 infant - very premature.de. </P>
<P>5 Infant - low birth weight.de. </P>
<P>6 Infant - very low birth weight.de. </P>
<P>7 Premature birth.de. </P>
<P>8 Infant - small for gestational age.de.</P>
<P>9 (neonat$ or neo nat$).ti,ab. </P>
<P>10 (newborn$ or new born$ or newly born$).ti,ab.</P>
<P>11 (preterm or preterms or pre term or pre terms).ti,ab. </P>
<P>12 (preemie$ or premie or premies).ti,ab. </P>
<P>13 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab.</P>
<P>14 (low adj3 (birthweight$ or birth weight$)).ti,ab. </P>
<P>15 (lbw or vlbw or elbw).ti,ab.</P>
<P>16 infan$.ti,ab. </P>
<P>17 (baby or babies).ti,ab. </P>
<P>18 Enterocolitis.de. </P>
<P>19 enterocolitis.ti,ab. </P>
<P>20 NEC.ti,ab.</P>
<P>21 or/1-20</P>
<P>22 Glutamine.de. </P>
<P>23 glutam$.ti,ab. </P>
<P>24 levoglutam$.ti,ab. </P>
<P>25 22 or 23 or 24 </P>
<P>26 21 and 25 </P>
<P>27 limit 26 to yr="2007 -Current" </P>
<P>
<B>Key</B>
</P>
<P>.de. = indexing term</P>
<P>$ = truncation</P>
<P>.ti,ab. = terms in either title or abstract fields</P>
<P>adj3 = terms within three words of each other (any order)</P>
<P>yr = year published</P>
<P>
<B>MEDLINE</B>
</P>
<P>OvidSP <A HREF="http://ovidsp.ovid.com/">http://ovidsp.ovid.com/</A>
</P>
<P>The Cochrane highly sensitive search strategy for identifying randomized trials in MEDLINE (sensitivity-maximizing version) was used to limit retrieval to clinical trials (lines 21-31) (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>1 exp Infant, Newborn/ </P>
<P>2 Premature Birth/</P>
<P>3 (neonat$ or neo nat$).ti,ab. </P>
<P>4 (newborn$ or new born$ or newly born$).ti,ab. </P>
<P>5 (preterm or preterms or pre term or pre terms).ti,ab. </P>
<P>6 (preemie$ or premie or premies).ti,ab.</P>
<P>7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab.</P>
<P>8 (low adj3 (birthweight$ or birth weight$)).ti,ab.</P>
<P>9 (lbw or vlbw or elbw).ti,ab. </P>
<P>10 infan$.ti,ab.</P>
<P>11 (baby or babies).ti,ab.</P>
<P>12 Enterocolitis, Necrotizing/ </P>
<P>13 enterocolitis.ti,ab. </P>
<P>14 NEC.ti,ab. </P>
<P>15 or/1-14 </P>
<P>16 Glutamine/ </P>
<P>17 glutam$.ti,ab. </P>
<P>18 levoglutam$.ti,ab.</P>
<P>19 16 or 17 or 18 </P>
<P>20 15 and 19 </P>
<P>21 randomized controlled trial.pt. </P>
<P>22 controlled clinical trial.pt. </P>
<P>23 randomized.ab. </P>
<P>24 placebo.ab. </P>
<P>25 drug therapy.fs.</P>
<P>26 randomly.ab. </P>
<P>27 trial.ab. </P>
<P>28 groups.ab.</P>
<P>29 or/21-28</P>
<P>30 exp animals/ not humans.sh. </P>
<P>31 29 not 30 </P>
<P>32 15 and 19 and 31</P>
<P>33 limit 32 to ed=20111101-20140911 </P>
<P>
<B>Key</B>
</P>
<P>/ = indexing term (MeSH heading)</P>
<P>exp = exploded MeSH heading</P>
<P>$ = truncation</P>
<P>.ti,ab. = terms in either title or abstract fields</P>
<P>adj3 = terms within three words of each other (any order)</P>
<P>.pt. = publication type</P>
<P>.fs. = floating subheading</P>
<P>.sh.= subject heading</P>
<P>.ed. = entry date - date added to the database</P>
<P>
<B>MEDLINE In-Process &amp; Other Non-Indexed Citations</B>
</P>
<P>OvidSP <A HREF="http://ovidsp.ovid.com/">http://ovidsp.ovid.com/</A>
</P>
<P>1 exp Infant, Newborn/ </P>
<P>2 Premature Birth/ </P>
<P>3 (neonat$ or neo nat$).ti,ab. </P>
<P>4 (newborn$ or new born$ or newly born$).ti,ab. </P>
<P>5 (preterm or preterms or pre term or pre terms).ti,ab.</P>
<P>6 (preemie$ or premie or premies).ti,ab. </P>
<P>7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. </P>
<P>8 (low adj3 (birthweight$ or birth weight$)).ti,ab. </P>
<P>9 (lbw or vlbw or elbw).ti,ab. </P>
<P>10 infan$.ti,ab. </P>
<P>11 (baby or babies).ti,ab. </P>
<P>12 Enterocolitis, Necrotizing/ </P>
<P>13 enterocolitis.ti,ab.</P>
<P>14 NEC.ti,ab. </P>
<P>15 or/1-14</P>
<P>16 Glutamine/ </P>
<P>17 glutam$.ti,ab.</P>
<P>18 levoglutam$.ti,ab.</P>
<P>19 16 or 17 or 18 </P>
<P>20 15 and 19</P>
<P>21 limit 20 to ed=20111101-20140918</P>
<P>
<B>Key</B>
</P>
<P>/ = indexing term (MeSH heading)</P>
<P>exp = exploded MeSH heading</P>
<P>$ = truncation</P>
<P>.ti,ab. = terms in either title or abstract fields</P>
<P>adj3 = terms within three words of each other (any order)</P>
<P>ed = entry date - date added to the database</P>
<P>
<B>PubMed</B>
</P>
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/">http://www.ncbi.nlm.nih.gov/pubmed/</A>
</P>
<P>The Cochrane highly sensitive search strategy for identifying randomized trials in PubMed (sensitivity-maximizing version) was used to limit retrieval to clinical trials (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>Search (((((((((((((((((((((("Infant, Newborn"[Mesh])) OR ("Premature Birth"[Mesh])) OR (((neonat*[Title/Abstract]) OR neo nat*[Title/Abstract]) OR neo-nat*[Title/Abstract])) OR (((((newborn*[Title/Abstract]) OR new born*[Title/Abstract]) OR new-born*[Title/Abstract]) OR newly born*[Title/Abstract]) OR newly-born*[Title/Abstract])) OR ((((((preterm[Title/Abstract]) OR preterms[Title/Abstract]) OR pre term[Title/Abstract]) OR pre-term[Title/Abstract]) OR pre terms[Title/Abstract]) OR pre-terms[Title/Abstract])) OR (((preemie*[Title/Abstract]) OR premie[Title/Abstract]) OR premies[Title/Abstract])) OR ((prematur*[Title/Abstract]) AND birth*[Title/Abstract])) OR ((prematur*[Title/Abstract]) AND born[Title/Abstract])) OR ((prematur*[Title/Abstract]) AND deliver*[Title/Abstract])) OR ((low[Title/Abstract]) AND birthweight*[Title/Abstract])) OR ((low[Title/Abstract]) AND birth weight*[Title/Abstract])) OR ((low[Title/Abstract]) AND birth-weight*[Title/Abstract])) OR (((lbw[Title/Abstract]) OR vlbw[Title/Abstract]) OR elbw[Title/Abstract])) OR (infan*[Title/Abstract])) OR ((baby[Title/Abstract]) OR babies[Title/Abstract])) OR ("Enterocolitis, Necrotizing"[Mesh:noexp]) OR (enterocolitis[Title/Abstract]) OR (NEC[Title/Abstract]))) AND (((levoglutam*[Title/Abstract]) OR glutam*[Title/Abstract]) OR "Glutamine"[Mesh:noexp]))) AND (((((((((((randomized controlled trial[Publication Type])) OR (controlled clinical trial[Publication Type])) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract])) OR (drug therapy[MeSH Subheading])) OR (randomly[Title/Abstract])) OR (trial[Title/Abstract])) OR (groups[Title/Abstract]))) NOT (animals[mh] NOT humans[mh])))) AND ("2011/11/01"[Date - Entrez] : "3000"[Date - Entrez])</P>
<P>
<B>Key</B>
</P>
<P>[Mesh] = exploded Medical Subject heading (MeSH)</P>
<P>[mh] = exploded MeSH</P>
<P>[Mesh:noexp] = MeSH not exploded</P>
<P>* = truncation</P>
<P>[Title/Abstract] = terms in either title or abstract fields</P>
<P>[Date - Entrez] = entry date - date added to the database</P>
<P>
<I>
<B>Trial register searches</B>
</I>
</P>
<P>
<B>Clinical Trials.gov</B>
</P>
<P>
<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>
</P>
<P>Glutamine AND (infant OR infants OR newborn OR newborns OR premature OR prematurity OR neonate OR neonates OR neonatal OR preterm OR preterms OR preemie OR preemies OR premie OR premies OR birthweight OR baby OR babies) | received on or after 11/01/2011 | updated on or after 11/01/2011</P>
<P>1 study found for: Glutamine AND (NEC OR enterocolitis) | received on or after 11/01/2011 | updated on or after 11/01/2011</P>
<P>12 studies found for: "Glutamine" | Child | received on or after 11/01/2011 | updated on or after 11/01/2011</P>
<P>
<B>metaRegister of Controlled Trials (mRCT)</B>
</P>
<P>
<A HREF="http://www.controlled-trials.com/mrct/searchform">http://www.controlled-trials.com/mrct/searchform</A>
</P>
<P>(Glutamine AND (infant OR infants OR newborn OR newborns OR premature OR prematurity OR neonate OR neonates or neonatal OR preterm OR preterms OR preemie OR preemies OR premie OR premies OR birthweight OR baby OR babies OR enterocolitis or NEC))</P>
<P>
<B>WHO International Clinical Trials Registry Platform</B>
</P>
<P>
<A HREF="http://apps.who.int/trialsearch/AdvSearch.aspx">http://apps.who.int/trialsearch/AdvSearch.aspx</A>
</P>
<P>1. glutam* in title, clinical trials in children</P>
<P>2. glutam* in intervention field, clinical trials in children</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>